Using Small Molecules and Peptides as Chemical Tools to Study Metal-Amyloid, Membrane-Amyloid, and Peptide-Amyloid Interactions. by Pithadia, Amit S.
Using Small Molecules and Peptides as Chemical Tools to Study Metal-Amyloid, 
Membrane-Amyloid, and Peptide-Amyloid Interactions 
by 
 
Amit S. Pithadia 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Chemistry) 
in the University of Michigan 
2016 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
  
 Professor Ayyalusamy Ramamoorthy, Co-Chair 
 Professor Carol A. Fierke, Co-Chair 
Professor Zaneta Nikolovska-Coleksa 
Professor Brandon Ruotolo 
 Professor John P. Wolfe 
© Amit S. Pithadia 
2016 
 
 
 
 ii 
Acknowledgements 
First and foremost, I would like to thank my advisers, Professor Ayyalusamy 
Ramamoorthy and Professor Carol Fierke for their dedication, support and enthusiasm for 
research throughout my time at the University of Michigan. They are truly incredible mentors 
and individuals. They helped me during desperate times and without their guidance and 
mentorship, I would not have completed my Ph.D. I am very lucky to have two brilliant and 
energetic advisers who have helped shape me into the researcher I am today. Importantly, they 
have instilled in me the values of being a diligent student, both academically and in life. 
I would also like to acknowledge my committee Professors John Wolfe, Brandon 
Ruotolo, and Zaneta Nikolovska-Coleska. Professor Wolfe has been a remarkable teacher and 
has encouraged me throughout the course of graduate school. He has also been great at putting 
science and life into perspective.  Additionally, Professor Ruotolo has been a frequent 
collaborator and valuable resource for my projects. His knowledge of amyloids has helped shape 
many of the problems on during my dissertation. I would like to also acknowledge Professor 
Ruotolo’s group members, specifically Dr. Molly Soper and Dr. Richard Kerr for providing 
insights into science and being available for meaningful discussions.  Lastly, Professor 
Nikolovska-Coleksa has been very positive and enthusiastic to learn about my projects and see 
my progression over the years. She has always provided great feedback and asked meaningful 
questions which has helped me understand my projects from a different light. 
I would like to acknowledge Professor Mi Hee Lim and her group members. I began my 
Ph.D in her laboratory and she truly helped me become a critical thinker as well as helped 
 iii 
broaden my experimental scope. It was a pleasure working for her and much of my degree is 
owed to her support and mentorship. It was a great experience working alongside intelligent and 
charismatic scientists in the Lim lab, specifically, Dr. Joseph Braymer, Dr. Jung-Suk Choi, Dr. 
Alaina DeToma, Dr. Michael Beck, and Dr. Masha Savelieff.  Drs. Braymer and DeToma were 
my scientific big brother and sister, respectively and are two individuals I could always count on 
to help me through good and bad times.  
I would additionally like to thank past and present members of the Ramamoorthy and 
Fierke groups that have provided support and plentiful insights throughout my time at UM. A 
special thanks to my endearing RAMyloiders: Dr. Patrick Walsh, my fellow flannel Friday 
followers: Dr. Sam Kotler and Kyle Korshavn, Dr. Jeffrey Brender, Kian Kamgar-Parsi, Dr. 
Anirban Bhunia, and the talented Michael McCullough. Additional gratitude to Dr. Kamal 
Mroue, Dr. Kazutoshi Yamamoto, Dr. Rongchun Zhang, Meng Zhang and Katie Gentry who 
been critical toward my progress as well as the best morning coffee group at U of M. Members 
of the Fierke lab have been great asset to help me assimilate into my new settings and expose me 
to different areas of science I was not familiar with. A special thank you is due to Andrea 
Stoddard who worked with me from the beginning to help me understand molecular biology and 
protein prep. Dr. Byungchul Kim, Dr. Michael Howard and Eric Sullivan, for always providing 
me with laughs and the afternoon pick-me-up coffee.  
Furthermore, I would like to thank my family (parents, siblings, aunts, uncles, 
grandparents, cousins, etc.). It was difficult for them to have me away from home for so long, but 
their unconditional love and support is the reason I am who I am today, someone they can be 
proud of. My parents, Snehal and Asha have always been my brain and heart, teaching me 
compassion, humility and respect. My brothers, Hiral and Sagar have always been my arms and 
 iv 
legs, giving me support and strength. Both of my grandmothers, though do not understand 
anything I do, have cheered me on since day 1. Without my friends, I would not have an outlet. 
There are too many people to name here, but each and every single person that has stayed with 
me through this journey has had their role in my success and I owe them a special thanks from 
the bottom of my heart. Always save the best for last. I would like to thank my fiancée, Namrata 
(Niki) for being my rock, my cheerleader and my friend. Without her, I would not be a hard-
working, patient, fun man I am today.  
  
 
 v 
Table of Contents 
 
Acknowledgements ......................................................................................................................... ii 
List of Figures ................................................................................................................................ vi 
List of Tables……………………………………………………………………………………viii 
List of Appendices ......................................................................................................................... ix 
Abstract...... ..................................................................................................................................... x 
Chapter 1: Introduction ................................................................................................................... 1 
Chapter 2: Reactivity of Diphenylpropynone Derviatives Toward Metal-Associated Amyloid-β 
Species ....................................................................................................................... 25 
 
Chapter 3: Influence of a Curcumin Derivative on hIAPP Aggregation in the Absence and 
Presence of Membrane Lipids………………………………………………………49 
 
Chapter 4: Self Assembly of a 9-Residue Peptide Fragment of SARS Corona Virus E-protein:  
Mechanism of Self Aggregation and Amyloid-Inhibition of hIAPP ........................ 65 
 
Chapter 5: Conclusions and Future Directions ........................................................................... 101 
Appendices……………………………………………………………………………………...108 
 
 vi 
List of Figures 
Figure 1.1 Kinetic growth model for amyloid proteins…………………………………………...2 
Figure 1.2 Amyloid aggregation and membrane disruption………………………………………8 
Figure 1.3 Chemical structures of polyphenolic small molecules.................................................12 
Figure 1.4 Comparison of rates of monomer consumption and fiber formation………………...14 
Figure 1.5 Possible influence of ligands on hIAPP aggregation………………………………...17 
Figure 2.1 Incorporation approach and structures of small molecules…………………………..26 
Figure 2.2 Solution speciation of DPP1 and DPP2……………………………………………...35 
Figure 2.3 Interaction of DPP1 and DPP2 with Cu2+ and Zn2+………………………………..36 
Figure 2.4 Solution speciation investigation of Cu2+-DPP2 complexes………………………...37 
Figure 2.5 Interactions of DPP1 and DPP2 with Aβ species. ……………………………………40 
Figure 2.6 Inhibition of Aβ with DPP1 and DPP2………………………………………………43 
Figure 3.1 Chemical structures of curcumin and CurDAc………………………………………50 
Figure 3.2 Inhbition of IAPP by CurDAc………………………………………………………..59 
Figure 3.3 CD spectra of hIAPP and CurDAc…………………………………………………...61 
Figure 3.4 Thioflavin T measurements of hIAPP and CurDAc………………………………….62 
Figure 4.1 DLS and CD spectra of TK9 and variants……………………………………………77 
Figure 4.2 EM micrographs of TK9 fibril……………………………………………………….80 
Figure 4.3 Time course tyrosine fluorescence spectra of TK9…………………………………..81 
Figure 4.4 Time course 1D 1H NMR spectra of TK9…………………………………………...82 
Figure 4.5 Residue-wise relaxation profile………………………………………………………83 
 vii 
Figure 4.6 H-bond analysis of TK9 monomer…………………………………………………...84 
Figure 4.7 SASA predictions for TK9 monomer and aggregate………………………………...87 
Figure 4.8 Measurements of TK9 and hIAPP interaction……………………………………….89 
Figure A.1 Cu2+ binding studies of DPP2 and Aβ…………………………………………….109 
Figure A.2 Metal selectivity studies of DPP1 and DPP2………………………………………110 
Figure A.3 Mass spectra of DPP1 and DPP2 with Aβ…………………………………………111 
Figure A.4 Docking studies…………………………………………………………………….112 
Figure A.5 Disaggregation experiment of Aβ with DPP1 and DPP2…………………………..114 
Figure A.6 Cytotoxicity studies………………………………………………………………...115 
Figure B.1 Stability and solubility of CurDAc…………………………………………………116 
Figure B.2 TEM micrographs of hIAPP and CurDAC inhibition experiment…………………117 
Figure B.3 DLS of hIAPP inhibition…………………………………………………………...118 
Figure B.4 Depolymerization of hIAPP by CurDAc…………………………………………...119 
Figure B.5 POPC/POPG LUV Dye Leakage spectra…………………………………………..120 
Figure B.6 Concentration Dependent inhibition of hIAPP by CurDAc………………………..121 
Figure C.1 TK9 extended conformation………………………………………………………..126 
Figure C.2 Different time-step assembly simulations…………………………………………..127 
Figure C.3 Reconstruction of all atom system from coarse-grained mode1……………………128 
Figure C.4 Time course DLS monitoring TK9 fibrillation……………………………………..129 
Figure C.5 SEM of YR5 and SK4 aggregates………………………………………………….130 
Figure C.6 Type and number of ROE contacts for TK9………………………………………..131 
Figure C.7 2D 1H/1H ROESY and generated TK9 structures…………………………………132  
 
 viii 
 
 
 
List of Tables 
 Table A.1 Raw MS signal intensity…………………………………………………………....108 
Table C.1 Mdp-parameters for reconstruction simulations…………………………………….122 
Table C.2 Structural statistics for NMR structures of TK9…………………………………….123 
Table C.3 Secondary structure distribution………………………………………………….....124 
Table C.4 Salt bridge interactions………………………………………………………………124 
Table C.5 Cation-pi interactions………………………………………………………………..125 
 
 
 
 ix 
List of Appendices 
Appendix A. Supporting Information for Chapter 2 ................................................................... 108 
Appendix B. Supporting Information for Chapter 3 ................................................................... 116 
Appendix C. Supporting Information for Chapter 4……………………………………………122 
 x 
Abstract 
 
Amyloid proteins are a family a proteins that are characterized by the misfolding an 
intrinsically disordered monomer subunit into an ordered beta-sheet fibril. Recent evidence has 
suggested that the monomer and fibril species are relatively inert; however, aggregates along the 
misfolding pathway are directly linked to cytotoxicity. It is known that biological cofactors and 
membranes may play a part in these deleterious events. Specifically metal ions and lipid bilayers 
may have a role in amyloid-associated toxicity through misregulation of metal ions and 
generation of oxidative stress with redox active metal ions or disruption of membrane integrity 
through pore formation and fragmentation of the bilayer. In order to better understand how metal 
ions and lipid bilayers are involved with amyloid aggregation and toxicity, small molecules can 
be used as chemical tools. A series of diphenylpropynone derivatives were developed to study 
the interaction of bifunctional ligands on metal-Aβ aggregation. Both DPP1 and DPP2 showed 
reactivity toward metal–Aβ species over metal-free Aβ species to different extents. In 
particular, DPP2, which contains a dimethylamino group, exhibited greater reactivity with 
metal–Aβ species than DPP1. Small molecules can also be applied as chemical modulators for 
lipid-associated amyloid aggregation. A curcumin derivative, CurDAc, was developed to 
investigate the mitigation of hIAPP aggregation in the absence and presence of lipid membrane. 
CurDAc showed tremendous inhibitory propensity for both lipid-free and lipid-assisted IAPP 
aggregation in vitro, making it an ideal candidate for further SAR studies. 
 xi 
To gain insights into the misfolding pathway and oligomerization of amyloid proteins, 
the self-assembly of TK9, a nine-residue peptide and its variants were characterized through 
biophysical, spectroscopic, and simulated studies, and it was confirmed that the structure of these 
peptides influences their aggregation propensity, hence, mimicking amyloid proteins. This 
peptide also showed promise as a chemical inhibitor for hIAPP aggregation. 
Through this work, insights into effective structural scaffold to modify amyloid 
aggregation in the presence of biological cofactors are understood. Moreover, the discovery of a 
structural scaffold to monitor oligomer and fibril formation in order to elucidate species along 
the misfolding pathway has also been made. 
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Chapter 1: Introduction 
 
Portions of this chapter have been adapted from the following publications:  
Pithadia A. S.; Lim, M. H. Curr. Opin. Chem. Biol. 2012, 16, 67-73. 
 
Patel, H. R.; Pithadia, A. S.; Brender, J. R.; Fierke, C. A.; Ramamoorthy, A. J. Phys Chem. Lett. 
2014, 5, 1864.  
 
Pithadia, A. S.; Brender, J. A.; Fierke C. A.; Ramamoorthy, A. J. Diabetes Res., 2016. Article 
ID 2046327, doi: 10.1155/2016/2046327.  
 
 
1.1  Introduction 
Amyloidosis is a condition belonging to a growing family of degenerative systemic and 
neurological diseases in which major component of degenerative processes is the amyloid 
formation.[1] These amyloids are insoluble deposits formed by protein precursor assembles into 
highly ordered β-sheet-rich fibers observed in distinctly intracellular and extracellular 
locations.[2,3] Amyloids are characterized by a cross-β sheet quaternary structure, in which 
individual beta-strands are thought to be oriented orthogonal to the long fiber axis.[4] Diseases, 
such as Alzheimer’s, and Type II Diabetes, have also been linked with the formation of such 
complex misfolded amyloid proteins (amyloid-β (Aβ) and human islet amyloid polypeptide 
(hIAPP), respectively); however, there appears to be little or no sequence homology between the 
peptides involved in the various amyloid diseases.[5] A growing body of evidence suggests that 
fibril formation may follow similar pathways: a nucleation process (Figure 1.1), in which the 
formation of numerous small oligomeric assemblies, also known as prefibrillar aggregates, of 
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proteins is believed to precede the formation of mature fibrils and be closely associated with cell 
death and cytotoxicity.[6-9]  
 
 
 
 
 
 
 
Figure 1.1. Kinetic growth model of amyloid proteins. During the lag phase, there is the 
intrinsicly disordered monomer aggregates to form low molecular weight oligomers and 
protofibrils which then self associate during the elongation phase to form insoluble protenacious 
fibrils. 
 
1.1.1 Amyloid-beta (Aβ) 
Monomeric Aβ peptides (39 − 43 amino acids in length) are generated via the cleavage of 
amyloid precursor protein (APP) by β− and γ−secretases [10-14]. These peptides are composed 
of a hydrophilic N-terminal region (1 − 28) and a hydrophobic C-terminal region (29 − 39/43). 
Two common forms of amyloidogenic Aβ peptides found in the AD brain are Aβ1-40 and Aβ1-42, 
with present indication being that Aβ1-42 is the predominant component in senile plaques; it is 
also considered to be more toxic than Aβ1-40 [10-13]. The generated monomeric Aβ species have 
the capability to aggregate, mainly through hydrophobic interactions [1]. Residues L17 – A21 
and G29 – M35 have been suggested to form an internal β-sheet structure, which is stabilized by 
a salt bridge (residues K28 and D23/E22). L17 – A21 have been suggested to be a self-
recognition site  which can be important in forming higher order structures via hydrophobic 
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interactions. Aβ  monomers and dimers containing these β-sheet structures can have contacts 
(e.g. hydrophilic interactions and hydrogen bonding) to form further aggregated species (e.g., 
oligomers, fibrils). Recent reports indicate that low molecular weight oligomeric Aβ species may 
be the most relevant to AD pathogenesis [11,14,15]. It is, however, still not completely 
understood which conformation of Aβ species is responsible for the pathology of AD.  
1.1.2 Islet Amyloid Polypeptide (IAPP) 
Islet Amyloid Polypeptide (IAPP, also known as amylin) is a 37-residue hormone 
produced and secreted in the pancreas has a role in controlling metabolic functions.[16] There is 
strong evidence which suggests that the aggregation of hIAPP plays a significant role in β-cell 
death, an important step in the transition from insulin resistance to overt type II diabetes.[17] It is 
well known through in vitro, tissue culture, and postmortem clinical examinations that hIAPP 
aggregate formation is correlated with the development of type II diabetes and can be implicated 
in the severity of the disease.[17] A causative role for IAPP in the etiology of type II diabetes has 
become clearer in recent years with the development of transgenic animal models that express 
the human variant of IAPP. Animals (such as rats) which do not spontaneously develop type II 
diabetes have an IAPP variant which does not readily form amyloid fibers and is also non-
cytotoxic.[18] However, transgenic rats expressing the amyloidogenic hIAPP develop type II 
diabetes with metabolic characteristics similar to human type II diabetes.[19,20] A current 
hypothesis is that overt type II diabetes develops when a combination of genetic and 
environmental factors, most of which are unknown at present, make an individual susceptible to 
β-cell death induced by hIAPP aggregation.[17] In the prediabetic stage of diabetes, insulin 
resistance is partly compensated for by increased insulin production.[21] However, increased 
insulin production also leads to increased hIAPP production as both are co-secretion products, 
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hence, physiologically connected.[16] The increased production of hIAPP in the prediabetic 
stage is believed to lead to the death of β-cells, starting a biochemical cycle that progresses as the 
disease worsens into overt type II diabetes.[17] Although hIAPP aggregation is not likely to be 
the sole cause of diabetes, it is proposed to play a major role in the development and progression 
of the disease. 
1.1.3 Metal Ions and Aβ 
Metal ions play essential roles throughout the body, especially in the brain [13,22−25]. 
Maintaining the homeostasis and compartmentalization of metal ions in the brain is necessary for 
proper neurological functions. Evidence has demonstrated that transition metals such as Cu, Zn, 
and Fe are colocalized in high micromolar to low millimolar concentrations in amyloid plaques 
(ca. 0.4 mM for Cu, 1 mM for Zn, and 0.9 mM for Fe) [11,13,14,25,26]. This observation may 
serve as a link to explain metal ion dyshomeostasis in the AD brain.  
Copper (Cu) exists under physiological conditions in both reduced (Cu(I)) and oxidized 
(Cu(II))  forms and is controlled tightly by biological ligands (e.g., proteins) [22-24]. Zinc, on 
the other hand, is not redox active and exists as Zn(II) in biological systems. Both Cu and Zn 
ions have been found to serve a role in neurotransmission activity and are present in micromolar 
concentrations in the synaptic cleft [13,24-27]. Also, Cu and Zn have been shown to co-purify 
with Aβ plaques in post mortem brains. Different from Cu and Zn, Fe has not been determined to 
co-purify with Aβ, but is still present in high amounts in Aβ plaques [13,27]. Taken together, the 
findings of the abundant levels of Cu, Zn, and Fe in Aβ plaques have triggered extensive 
investigations of metal-Aβ interaction/reactivity and its implications in AD pathology.  
 Through a variety of techniques, Cu(II) and Zn(II) have been shown to interact with Aβ 
in a 1:1 metal to Aβ binding stoichiometry; however, binding modes and coordination 
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environments of metal ions in Aβ are variable and dependent on experimental conditions [14, 
26-32]. Though Cu-Aβ can exist in many forms depending on pH, in the physiological pH range 
primarily exists in two forms: component I (between pH 6.0 and 8.0) and component II (slightly 
above pH 8.0. At pH 7.4 (physiological pH), it has been observed that Cu(II) binding to 
Aβ involves three nitrogen donor atoms and one oxygen donor atom (3N1O, component I). In 
this binding mode, the nitrogen donor atoms are possibly from three histidine (His) residues 
(His6, His13, His14) or two His ligands and the amine of the N-terminal region. Based on EPR 
and isotopic labeling studies the source of the oxygen donor atom has most likely been proposed 
to be from Asp1 in both nitrogen binding modes [33]. At pH ca. 8.0, metal binding (component 
II) can occur via three His residues (nitrogen donor atoms) and the carbonyl group of Ala2 
(oxygen donor atom) or a combination of the N-terminal amine, a His residue and amide 
backbone nitrogen, and carbonyl from Ala2 [33]. It has also been proposed that the four 
coordinating ligands in component II are the N-terminal amine or a deprotonated backbone 
amide with three His residues. In the case of Zn(II), the metal ion has shown to bind to Aβ via 
three His residues, but a total of four to six coordinating ligands on the metal center has been 
suggested [14,28,29]. Other ligands proposed to be involved in Zn(II) binding are Asp1, Glu11, 
and possibly, Arg5. Unlike Cu(II) and Zn(II), relatively less has been known about the 
coordination of Fe(II/III) and Cu(I) to Aβ species [28,34-38]. Studies have proposed a two 
coordinate linear binding geometry of monomeric Aβ  to Cu(I) and oligomeric Aβ-Cu(I) 
complexes have a tetrahedral coordination geometry [36]. Overall, metal ions have been 
demonstrated to bind to Aβ species through nitrogen and oxygen sources in the peptide. 
1.1.4 Metal-Aβ-Induced Neurotoxicity 
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Metal-Aβ species have been studied to determine their contribution to AD 
neuropathogenesis [14, 39-41]. Several findings have suggested that two avenues for metal-Aβ 
species are linked to neurotoxicity: The facilitation of Aβ aggregation and the induction of 
oxidative stress through ROS generation, leading to neuronal cell death and cognitive 
impairment. 
Both Cu and Zn ions, found at and around the synapse, could be involved in the process 
of generating Aβ aggregates and their accumulation in the synaptic cleft [24-26,29,41].  At 
physiological pH, Zn(II) could cause Aβ to aggregate into amorphous insoluble aggregates 
within milliseconds at concentrations below 100 mM [42,43]. Depending on experimental 
conditions, Cu(II) could promote the formation of fibrillar or amorphous aggregates and also 
accelerate the rate of nucleated aggregate formation relative to metal-free conditions [43]. These 
studies demonstrate that Aβ aggregation can be advanced in the presence of metal ions. The 
neurotoxic effects that could be induced by metal-Aβ species may be related to the disruption of 
membranes leading to apoptosis and/or aggregate accumulation at and around the synapse 
resulting in weakened cell signaling and neuronal death [11]. 
The second avenue of neurotoxicity is associated with oxidative stress. Cu(I/II) and 
Fe(II/III) are redox active metal ions and can undergo redox cycling in the presence of dioxygen 
(O2) and a reducing agent producing ROS [10,11,13,39-41]. When metal ions are surrounded by 
Aβ species, ROS such as hydrogen peroxide (H2O2) and hydroxyl radicals (•OH) can be 
generated. Though a clear understanding of the mechanistic pathway is presently unknown, it has 
been suggested that internal sources such as Met35 at C-terminus of Aβ or external sources such 
as ascorbate could provide electrons for the redox cycle [26]. Cu(I)-Aβ  oligomers can form a 
highly O2 reactive Cu(I) center, which can also assist in the formation of ROS [36]. In the AD 
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brain, an imbalance between production and removal of ROS can be observed. Along with the 
dysfunction of neuroprotective systems such as catalases and superoxide dismutases, the 
overproduction of ROS can trigger oxidative damage of biological targets (e.g., lipids, proteins, 
DNA) as well as oxidation of Aβ peptides (e.g., the formation of dityrosine bond (Tyr10-Tyr10) 
and three electron bond (Met35-Met35) between two peptides) resulting in the acceleration of 
Aβ  aggregation [11, 27].Overall, metal-induced Aβ aggregation and oxidative stress could be 
attributed to a high degree of neurotoxicity leading to neuronal death and ultimately, cognitive 
impairment. This correlation is still not completely understood; thus, further investigations are 
necessary in order to advance our understanding of metal-Aβ-involved neuropathogenesis in AD. 
1.1.5  Membranes play a critical role in both IAPP fibrillogenesis and toxicity 
  Fibrillization of IAPP can be affected by many factors. Of these, phospholipid 
membranes are perhaps the most important.[44,45] Membranes have a two-fold effect on IAPP. 
First, membranes can greatly accelerate the rate of fiber formation by IAPP.[46,47] Aggregation 
of IAPP, in turn, has been linked to numerous pathologies.[1] Some of these pathologies include 
the formation of reactive oxygen species in the presence of redox active metal ions,[48] 
endoplasmic reticulum stress caused by the accumulation of misfolded proteins,[49] and an 
inflammatory response triggered by IAPP amyloid fibers.[50,51] Membranes can therefore 
indirectly contribute to the cytotoxicity of IAPP by accelerating the formation of these toxic 
species. 
Second, and perhaps more importantly, IAPP can directly disrupt plasma and possibly 
organelle membranes during aggregation through two processes: the generation of pores and the 
eventual fragmentation of the lipid bilayer through a detergent-like mechanism (Figure 
1.2).[52,53] Disruption of cellular membranes leads to an immediate influx of Ca2+, which if not 
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controlled, initiates the process of apoptosis. Severe membrane disruption can lead to immediate 
necrosis through the leakage of critical cellular contents. The cell membrane therefore 
contributes both directly and indirectly to IAPP toxicity as both a site for the accumulation of 
toxic oligomers and as a target for their cytotoxic effect.  
 
           
Figure 1.2: Potential routes towards the formation of toxic oligomers and amyloid fibers from 
the monomeric state via multiple intermediate states. 
Traditionally, membrane disruption by amyloidogenic proteins has been thought to be the 
result of the formation of unregulated ion channels in the membrane that resemble traditional 
barrel-stave pores in many respects. In the channel hypothesis, small annular oligomers of IAPP 
possessing a hydrophobic exterior and hydrophilic interior insert into the membrane, spanning 
the bilayer.[54] The hollow structure of the oligomers allows ions to cross through the 
hydrophilic interior of the pore, causing an unregulated influx of Ca2+ into the cell (Figure 
1.2).[55] Since cells are highly sensitive to perturbations in ionic strength, a small perturbation in 
intracellular calcium levels caused by unregulated IAPP channels can trigger an apoptotic 
cascade.[56] 
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 While the channel hypothesis accounts for many facets of IAPP membrane disruption, it 
does not account for known facts about IAPP membrane interactions. First, large IAPP 
aggregates are the most disruptive to membranes, mirroring observations from other amyloid 
proteins.[57,58] This finding is surprising in light of the channel hypothesis, which would predict 
such large spherical aggregates could not easily form ion channels unless disassembled into 
smaller oligomers.[59] Second, aggregation of IAPP is often accompanied by large-scale 
morphological changes in the membrane, such as induction of excessive membrane curvature 
that would not be expected by the insertion of small oligomeric pores.[60-62] Finally, the time-
course of membrane disruption is strongly correlated with amyloid fibril formation and can be 
altered by seeding amyloid formation, implying a direct link between fibril formation and 
membrane disruption. It is difficult to reconcile this observation with a pore-dominated 
mechanism, as the dimensions of a fibril or protofibril are too large to form pores of a traditional 
type. These findings suggest the process of fiber formation disrupts the integrity of the 
membrane by some unknown process. Although it is fairly clear that a strong interaction between 
prefibrillar IAPP and the membrane is involved, the actual process by which IAPP and other 
amyloidogenic proteins fragment the membrane remains almost completely uncharacterized.  
1.1.6 Chemical Reagents for Targeting and Modulating Metal-Aβ Species 
In order to identify the relationship between metal-Aβ interaction/reactivity and AD 
initiation/progression, suitable chemical reagents, capable of targeting metal-Aβ species 
specifically and regulating their interaction/reactivity, would be valuable. For this purpose, 
current efforts have been directed toward a rational structure based design of small molecules 
that can directly interact with both metal ions and Aβ. [63-65] The basic concept of this design 
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principle is that the two structural moieties for bifunctionality (metal chelation and Aβ 
interaction) must be in the same molecule. 
Traditional metal chelators have been used to sequester and/or redistribute metal ions 
from metal-bound Aβ species in order to suppress metal-mediated Aβ aggregation and 
neurotoxicity in vitro and in vivo. Specifically, clioquinol (CQ, 5-chloro-7-iodo-8-
hydroxyquinoline) and its derivative (PBT2) have been able to reduce metal-induced Aβ 
aggregation, Aβ plaque deposition, and ROS generation in vitro and in vivo, leading to improved 
cognition [42,43]. In addition to the metal chelation property, the ability of the compounds to 
interact with Aβ is necessary in order to target metal-Aβ species specifically in heterogeneous 
settings like the brain. Among Aβ imaging agents, p-I-stilbene has been used and shown to have 
appropriate properties for brain applications (e.g., blood-brain barrier permeability) [68]. It has 
been illustrated that introducing different substituents into stilbene derivatives could tune their 
binding affinity for Aβ [64]. Thus, the frameworks from these known imaging agents are a small 
portion of known compounds which may be employed as Aβ interacting scaffolds toward the 
construction of new chemical reagents for metal-Aβ species. 
Utilizing the structural moieties for bifunctionality (metal chelation and Aβ interaction), 
two synthetic approaches (linkage and incorporation) have been taken to fashion small molecules 
toward targeting and modulating metal-Aβ species [13,14,63,64].  
On the basis of the incorporation approach, a metal chelation site can be directly installed 
into an Aβ interacting framework to produce a small molecule having bifunctionality (vide 
infra). As an example, the stilbene derivative, L2-b, was created via inclusion of two nitrogen 
donor atoms on the structure of an Aβ imaging agent (p-I-stilbene) [69]. L2-b has been shown to 
control metal-induced Aβ aggregation in vitro, as well as target and break down Aβ aggregates 
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isolated from human AD brain tissue homogenates containing a certain amount of metal ions. 
L2-b was also capable of diminishing ROS generation by Cu-Aβ in vitro and reducing metal-Aβ 
neurotoxicity in human neuroblastoma cells [69]. Specific disruption between metal ions and Aβ 
followed by the control of their reactivity using chemical reagents in the diseased settings could 
deepen our understanding of their direct correlation to the pathogenesis, which could contribute 
to new directions of diagnostic and therapeutic discovery for AD.  
1.1.6 Natural products are natural choices for amyloid intervention 
Particular areas of interest toward discovering agents against amyloidosis have been 
natural products. Natural products are small molecules found abundantly in nature, particularly 
in foods, and have been the main source for early medicines and therapeutics. They feature 
specific scaffolds that have made them beneficial receptor agonists, enzyme activators, inhibitors 
of protein-protein and DNA-protein interactions and channel openers.[70] Some natural products 
have also been shown to act as colloidal species which can sequester low molecular weight 
aggregates and prevent their fibrillation.[71] Importantly, natural products often exhibit better 
pharmacological profiles than their synthetic counterparts, especially with regard to toxicity and 
absorption.[70] Based on early successes, naturals products such as flavonoids and curcuminoids 
have been extensively researched in regards to reduction of the amyloid associated toxicity of Aβ 
and α-synuclein.  
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Figure 1.3. Chemical structures of the most studied polyphenolic small molecule inhibitors of 
hIAPP aggregation: Epigallocatechin Gallate (EGCG), Gallocatechin Gallate (GCG), 
Gallocatechin (GC), curcumin, and resveratrol. 
There have been two main approaches to blocking the toxicity associated with amyloid 
aggregation. The first approach is to reduce toxicity by preventing the toxic species from 
forming. The second approach attempts to mediate the effects of the toxic oligomer formation by 
serving as an antioxidant to reduce the reactive oxygen species (ROS) generated by the 
aggregation process,[72, 73] reduce inflammatory effects,[74] prevent membrane 
association,[75, 76] or block the channels created by the peptide.[77-80] Given their ability to 
target multiple facets of amyloid-associated toxicity through their anti-inflammatory, 
antioxidant, and anti-amyloidogenic properties,[81, 82] natural products make a very promising 
class of candidates as viable small molecule inhibitors toward amyloids, specifically hIAPP. 
Through more stringent investigations, the use of natural products as aggregation modulators of 
hIAPP has provided more direct structural information about the hIAPP aggregation process 
itself. Herein, we will discuss the application of small molecule natural products toward the 
modulation of hIAPP aggregation with a particular focus on the most studied natural products, 
epigallocatechin-3-gallate (EGCG), curcumin, and resveratrol (Figure 1.3). 
1.1.7 Methods to study amyloid aggregation and misfolding pathways 
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Identifying adequate structures of individual species involved in the fibrillation process is 
still extremely difficult.[83] Currently, most of the approaches to analyze the misfolding of IAPP 
are based on the Aβ protein, which is a more extensively studied amyloidogenic protein than 
hIAPP. A common method to investigate the process of fibril formation has been the thioflavin T 
(ThT) based fluorescence assay as it provides indirect evidence of how individual monomers 
convert into oligomeric species and eventually to the growth of fibrillar IAPP (Figure 1.4). 
Although this method is usually sensitive and reliable for most amyloidogenic proteins in the 
absence of other cofactors such as small molecule inhibitors, in some cases it cannot differentiate 
between oligomeric intermediates.[84] Furthermore, the ThT fluorescence is dependent on the 
surface charge of the fiber and therefore can give skewed results with alterations of pH[85] or 
when highly charged amyloidogenic proteins are considered.[86] A more serious complication 
occurs when small molecule inhibitors are introduced, as these often have either an intrinsic 
fluorescence that interferes with ThT detection[87] or bind to a similar site on the amyloid fiber, 
resulting in a false positive from competitive inhibition.[88]  
Another method to follow the conformational transitions involved in IAPP amyloid 
formation is circular dichroism (CD) (Figure 1.4).[89] Changes in secondary structure content 
can be followed through CD during the fibrillation process. While CD can effectively distinguish 
between monomers and aggregates, it does not distinguish specifically between amyloid fibers 
and other β-sheet containing aggregates and it needs to rely on other techniques for quantitative 
prediction in this respect. CD is also problematic in inhibition studies when compounds that 
absorb in the near-UV range are considered. Time evolution of the size of aggregates can be 
tracked by dynamic light scattering (DLS) but the heterogeneous nature of the aggregates pose 
tremendous challenges to the application of DLS experiments. And, the accuracy of light 
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scattering experiments on small complexes is severely affected by the presence of even a small 
percentage of high-molecular weight species such as amyloid fibers.[90] This can be partially 
eliminated by running the solution through a size exclusion column (SEC) prior to acquisition. 
However, in general, separation based techniques can suffer from serious artifacts when applied 
to weakly associating aggregates like early intermediates. A careful study showed that SDS gels, 
a common method for detecting non-fibrillar aggregates, can underestimate the size of oligomers 
by more than a factor of 20 by fragmenting larger oligomers.[91] Similar, although less severe, 
results have been obtained with SEC in the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Comparison of the rates of monomer consumption and fiber formation. (a) Overlay 
of kinetic traces obtained via 19F NMR (black), ThT fluorescence (red), and CD (blue). (b) Time 
course CD trace of hIAPP aggregation. (c and d) TEM micrographs of hIAPP at an early time 
point and late time point, respectively. (Reprinted with permission, Copyright © 2012, American 
Chemical Society).  
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absence of detergents.[92] Several other techniques such as Electron Microscopy (EM, Figure 
1.4) can detect the morphology of aggregates. Both transmission and scanning EM have been 
used comprehensively for low-resolution characterization and visualization of mature protein 
fibrils.[83] In particular, these techniques have proved invaluable for investigating membrane-
bound oligomers,[93] which are inaccessible to most other techniques. However, these methods 
suffer from extensive surface contact between amyloid and sample support,[83] and have been 
shown to show a bias towards certain oligomers with a high affinity towards the surface.[91] 
Real-time NMR is another promising alternative that fulfills most of the seven 
requirements listed above. NMR is moderately sensitive in modern spectrometers is non-
perturbative, can easily track aggregation in the presence of inhibitors using labeled protein 
samples, detects a broad range of oligomers within certain size limits, and can yield rapid 
atomic-level structural details. While most of the spectra obtained from common solution NMR 
experiments is only observable for smaller oligomers, larger oligomers (up to 50 nm) [94] give 
rise to a characteristic spectra that is easily identified by pulse field gradient experiments.[95-97] 
A particular advantage of real-time NMR is the large amount of data encoded even in a 1D 
experiment and its ability to track the individual components of a heterogeneous sample (for 
example monomers, small oligomers, amyloid fibers) separately, at equilibrium, and non-
perturbatively through differences in their chemical shift frequency or diffusion constants.[94,97] 
In this respect, real-time NMR can therefore provide a more clear understanding of the early 
stages of amyloid assembly and other amyloidogenic proteins. However, traditional NMR 
experiments on amyloids suffer from low sensitivity and low time resolution, severely limiting 
their applications to investigate a class of proteins that inherently have low solubility and display 
time-dependent aggregation. Despite these challenges, NMR has been able to track the 
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conformational changes that occur during aggregation in real-time for a limited number of 
amyloidogenic proteins.[98–100] In particular, the aggregation of hIAPP at pH 6 and 4 °C is 
slow enough that changes in 1H or 15N chemical shift values have provided residue specific 
information on the amyloid nucleation process. This study showed that the peaks for individual 
residues do not disappear uniformly. Instead, the N-terminal cross-peaks disappear before the C-
terminal cross-peaks, implying that the formation of large aggregates that are invisible to NMR 
begins with the formation of N-terminal contacts.  
Ion mobility-mass spectrometry (IM-MS) IM-MS is a dynamic tool, useful in the 
elucidation of protein mass and size. However, IM-MS data alone is often not enough to generate 
a complete model of amyloidogenic protein structure. In much of the literature, IM-MS results 
are presented in combination with other techniques such as NMR, X-ray crystallography, 
transmission electron microscopy (TEM), and gel electrophoresis. Useful information regarding 
the collisional cross section (CCS) paired with other biophysical data, these methods can provide 
a robust integrated framework from which to filter potential structural models for amyloid-
forming peptides as well as small-molecule and metal ion interactions with amyloid peptides and 
proteins. In general, IM-MS can help study protein oligomerization and interaction pathways 
along with affording rich information about how small molecule compounds interact with and 
reorganize protein aggregates thus providing a method to screen compounds and study how these 
small molecules modify the distribution of amyloid species in the gas phase. 
The ideal method for biophysical characterization would therefore be: (1) sensitive enough 
to pick up intermediate species that likely occur at low population; (2) not suffer from 
interference effects when used with small molecule inhibitors; (3) non-perturbative; (4) have a 
high distinguishing capability between different aggregates; (5) applicable to a broad range of 
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aggregates in terms of size and structure; (6) capable of providing an unbiased view of the total 
aggregates present, or at least an unbiased view of a subset that can be defined in a precise way; 
(7) yielding atomic-level structural details.   
1.2 Dissertation objectives 
It is evident that the events during the aggregation process of Aβ and hIAPP still have yet 
to be more clearly characterized. This does not even take into the factor the involvement of 
biological co-factors and biomolecules such as metal ions and lipid membranes. Though we now 
better understand how these systems are involved in protein assembly, there still remains a gap 
on how to target their specific interactions and mitigate their detrimental effects. The objectives 
of this thesis provide insights into methods on how to more clearly understand amyloid protein 
aggregation and provide methods on how to use small molecules and peptides to probe these 
interactions (Figure 1.5). 
 
Figure 1.5. Possible influences of ligands on hIAPP aggregation. Schematic illustrating some of 
the possible mechanisms by which an inhibitor can affect aggregation: (A) Monomer 
stabilization;  (B) Stabilization of off-pathway intermediates; (D and E) Dissolution of fibers 
either completely to the monomeric state (D) or incompletely to another oligomeric form (E); (F) 
Prevention of fiber extension. Note that this is not an exhaustive list of possible interactions. 
!
Figure 3. Possible influences of ligands on 
hIAPP aggregation. Schematic illustrating 
some of the possible mechanisms by which an 
inhibitor can affect aggregation: (A) Monomer 
stabilization;  (B) Stabilization of off-pathway 
intermediates; (D and E) Dissolution of fibers 
either completely to the monomeric state (D) or 
incompletely to another oligomeric form (E); (F) 
Prevention of fiber extension. Note that this is 
not an exhaustive list of possible interactions. 
(A) 
(B) 
(E) 
(D) 
(F) (C) 
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Furthermore, the objectives of this work looks closely at key structural components that 
are required to investigate metal-Aβ interactions, membrane-hIAPP interactions, and amyloid 
self-assembly.  In Chapter 2 the preparation, characterization, and metal–Aβ reactivity of two 
diphenylpropynone derivatives (DPP1 and DPP2) composed of structural moieties for metal 
chelation and Aβ interaction is presented. These compounds were capable of interacting with 
both metal ions and Aβ species, as well as regulating metal-induced Aβ aggregation in vitro. 
Particularly, DPP2, which contains a dimethylamino group, exhibited greater reactivity with 
metal–Aβ species than DPP1, suggesting a structure-reactivity relationship. Overall, our studies 
present a new bifunctional scaffold that could be utilized to develop chemical reagents for 
investigating metal–Aβ species in AD. The deposition of aggregates of human islet amyloid 
polypeptide (hIAPP) has been correlated with the death of β-cells in type II diabetes mellitus. 
The actual molecular mechanism of cell death remains largely unknown; however, it has been 
postulated that the process of aggregation from monomeric hIAPP is closely involved. A 
possible cause of cellular toxicity may be through the disruption of structural integrity of the cell 
membrane by IAPP. In Chapter 3, the utility of a water-soluble curcumin derivative, CurDAc, is 
used to investigate the mitigation of hIAPP aggregation in the absence and presence of the lipid 
membrane, thus giving insights into how we can functionalize natural products to increase their 
effectiveness toward studying amyloid-lipid interactions. Lastly, molecular self-assembly, a 
phenomenon widely observed in nature, has been exploited through organic molecules, proteins, 
DNA and peptides to study complex biological systems. These self-assembly systems may also 
be used in understanding the molecular and structural biology which can inspire the design and 
synthesis of increasingly complex biomaterials. Specifically, use of these building blocks to 
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investigate protein folding and misfolding has been of particular value since it can provide 
tremendous insights into peptide aggregation related to a variety of protein misfolding diseases, 
or amyloid diseases (e.g. Alzheimer’s disease, Parkinson’s disease, type-II diabetes). In Chapter 
4 the self-assembly of TK9, a 9 residue peptide of the extra membrane C-terminal tail of the 
SARS Corona virus envelope is characterized through biophysical, spectroscopic and simulated 
studies, and it was confirmed that the structure of these peptides influence their aggregation 
propensity, hence, mimicking amyloid proteins. TK9, which forms a beta-sheet rich fibril, 
contains a key sequence motif that may be critical for β-sheet formation, thus making it an 
interesting system to study amyloid fibrillation and inhibition through self-recognition. 
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Chapter 2: Reactivity of Diphenylpropynone Derviatives Toward Metal-Associated 
Amyloid-β  Species  
 
This chapter was adapted from the following publication:  
Pithadia, A. S.; Kochi, A.; Soper, M. T.; Beck, M. W.; Liu, Y.; Lee, S.; DeToma, A. S.; 
Ruotolo, B. T.; Lim, M. H. Inorg. Chem. 2012, 51, 12959.  I 
 
2.1. Introduction 
Alzheimer’s disease (AD) is a devastating and fatal neurodegenerative disease that 
affects over 5 million people in the United States.[1,2]  A pathological hallmark of the diseased 
brain is an accumulation of misfolded amyloid-β (Aβ) peptides and its aggregated forms (e.g., 
oligomers, protofibrils, fibrils).[2-6] Monomeric Aβ species result from the proteolytic cleavage 
of the transmembrane protein, amyloid precursor protein (APP) which can further aggregate to 
produce oligomers, protofibrils, and eventually fibrils.[2-5,7,8] It is still not completely 
understood which conformation of Aβ is associated with AD neuropathogensis; however, recent 
evidence has proposed that soluble oligomers might be the toxic species due to their ability to 
interrupt neurotransmission.[4,5,9]  
In addition, elevated concentrations of transition metals, such as Cu, Zn, and Fe, have 
been observed within the deposits of Aβ aggregates.[2,7,10-15] These metals serve important 
functions in the body, especially in the brain, and a misregulation may lead to adverse 
consequences.[2,7,8] The possible relationship between metal-associated Aβ species (metal–Aβ 
species) and neurotoxicity has been suggested based on observations that metal ions facilitate Aβ 
aggregation as well as enhance oxidative stress caused by reactive oxygen species 
(ROS).[2,4,5,7,8,12-21] It has not been, however, clearly revealed if and how metal–Aβ species 
are linked to AD pathology.  
                                                
I ASP – synthesis, metal binding, speciation; AK, YL  – gel assays; MTS – mass spec; MWB – 
docking; ASD – revising 
 26 
To gain a better understanding of this connection, previous efforts in metal chelation 
therapy were taken by utilizing metal chelators such as clioquinol (CQ) as tools to disturb the 
metal–Aβ interaction.[2,4,5,7,8,19,22] However, due to the lack of specificity of these metal 
chelators for Aβ, recent advancements in the development of chemical reagents to specifically 
target metal–Aβ species and modulate their interaction and reactivity have been 
made.[2,7,8,21,23-33] Among them, rationally-designed small molecules with metal chelation 
and Aβ interaction properties (defined as bifunctionality) have been constructed. Some of the 
compounds have been fashioned based on the incorporation approach (Figure 2.1), where a metal 
chelation site is directly inserted into the structure of a known Aβ imaging agent with minimal 
structural modifications, along with consideration of criteria for possible brain uptake.[8,21,23-
26,28-33] They have been able to control the interactions and reactivity of metal–Aβ species in 
vitro and/or in living cells, suggesting that the incorporation approach (Figure 2.1) could be 
considered as a promising design strategy to develop suitable chemical reagents for studying the 
involvement of metal–Aβ species in AD. Herein, we report the design, preparation, and 
characterization of a new class of bifunctional small molecules (DPP1 and DPP2, Figure 2.1) 
that were developed for targeting and regulating metal–Aβ species utilizing a diphenylpropynone 
framework. In addition, their reactivity with metal–Aβ species in vitro was investigated and 
described. Our recent findings suggest that the diphenylpropynone framework may be beneficial 
for targeting metal–Aβ species and altering their reactivity, as well as minor structural features 
such as the dimethylamino functionality may be responsible for a refined interaction with Aβ, 
thus potentially enhancing reactivity with metal–Aβ species. 
 
 
 
A  Interaction Metal Chelation 
Mn+ 
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+
Bifunctionality 
Mn+ 
O
N
125I
N
O
N
O
N
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Figure 2.1. Incorporation approach (top) and structures of small molecules (bottom). Left to 
right: 3-(4-(dimethylamino)-phenyl)-1-(4-iodophenyl)-2-propyn-1-one; DPP1 = 3-phenyl-1-
(pyridin-2-yl)-2-propyn-1-one; DPP2 = 3-(4-(dimethylami-no)phenyl)-1-(pyridin-2-yl)-2-
propyn-1-one. 
 
Materials and Procedures 
All reagents were purchased from commercial suppliers and used as received unless 
otherwise stated. The compound, 3-phenyl-1-(pyridin-2-yl)prop-2-yn-1-one (DPP1) was 
prepared following previously reported methods.[34-36] Aβ1-40 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG-LMVGGVV) was purchased from 
AnaSpec (Fremont, CA). An Agilent 8453 UV-Visible (UV-Vis) spectrophotometer was used to 
measure the optical spectra. Transmission electron microscopy (TEM) images were recorded 
with a Philips CM-100 transmission electron microscope. A SpectraMax M5 microplate reader 
(Molecular Devices, Sunnyvale, CA) was employed for the measurement of absorbance for 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and PAMPA-BBB assays. 
NMR spectra of small molecules and for Zn2+ binding studies were obtained by a Varian 400 
MHz NMR spectrometer. Mass spectrometric measurements for compounds were made using a 
Micromass LCT Electrospray Time-of-Flight mass spectrometer. Mass spectrometric studies for 
investigating the interaction of DPP1 and DPP2 with the peptide were carried out on a Waters 
Synapt G2 ion-mobility mass spectrometer (Milford, MA). 
Preparation of 3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)-2-propyn-1-one (DPP2). 
DPP2 was synthesized by slight modifications to a previously reported procedure.[36] To a 
solution of 4’-dimethylaminophenyl acetylene (0.42 g, 2.9 mmol) in dry tetrahydrofuran (THF, 5 
mL) was added n-butyllithium (0.72 mL, 2.9 mmol, 2.5 M solution in hexanes) dropwise by a 
syringe over 5 min at -40 °C. The reaction mixture was allowed to stir at -40 °C for 10 min and 
then warmed to -15 °C. After 30 min, the mixture was cooled to -78 °C (dry ice/acetone) and a 
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solution of Weinreb’s amide (0.40 g, 2.4 mmol in 9 mL of dry THF) was introduced through a 
syringe. The reaction mixture was allowed to react at -78 °C for 10 min and then warmed to 
room temperature and followed by 1 h stirring. The reaction was quenched by adding saturated 
aqueous NaHCO3 (2 mL), diluted with EtOAc (10 mL), and washed with brine (2 x 25 mL). The 
aqueous layer was extracted with EtOAc (2 x 15 mL), and the combined organic solutions were 
dried over MgSO4 and filtered, followed by removal of the solvent in vacuo. The crude product 
was purified by silica gel chromatography (CH2Cl2 : EtOAc = 9 : 1) to yield an orange product 
(202 mg, 0.81 mmol, 28%). 1H NMR (400 MHz, CDCl3)/δ (ppm): 8.77 (d, J = 4.8 Hz, 1 H), 8.14 
(d, J = 7.6 Hz, 1 H), 7.82 (td, J = 7.6, 1.6 Hz, 1 H), 7.57 (d, J = 8.4 Hz, 2 H), 7.44 (m, 1 H), 6.59 
(d, J = 8.4 Hz, 2 H), 2.98 (s, 6 H). 13C NMR (100 MHz, CDCl3)/δ (ppm): 177.6, 153.7, 151.8, 
149.7, 136.8, 135.6, 126.9, 123.3, 111.4, 105.5, 100.2, 89.3, 39.9. HRMS: Calcd for [M+H]+, 
251.1179; Found, 251.1176. 
Parallel Artificial Membrane Permeability Assay (PAMPA). PAMPA-BBB experiments 
were carried out using the PAMPA Explorer kit (pION Inc.) with modification to previously 
reported protocols.[30,37-39] Each stock solution was diluted with pH 7.4 Prisma HT buffer 
(pION) to a final concentration of 25 µM (1% v/v final DMSO concentration) and 200 µL were 
added to the wells of the donor plate (number of replicates = 12). BBB-1 lipid formulation (5 µL, 
pION) was used to coat the polyvinylidene fluoride (PVDF, 0.45 mM) filter membrane on the 
acceptor plate and brain sink buffer (BSB, 200 µL, pION) was added to each well of the acceptor 
plate. The acceptor plate was placed on top of the donor plate forming a “sandwich.” The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV-Vis spectra of the 
solutions in the reference, acceptor, and donor plates were measured using a microplate reader. 
The PAMPA Explorer software v. 3.5 (pION) was used to calculate the −logPe for each 
 29 
compound. CNS+/− designations were assigned by comparison to compounds that were 
identified in previous reports.[37-39] 
Determination of Solution Speciation for DPP1, DPP2, and the Cu2+–DPP2 Complex. The 
pKa values for DPP1 and DPP2 were determined by UV-Vis variable-pH titrations based on a 
previously reported procedure.[30] To establish the pKa values, a solution (100 mM NaCl, 10 
mM NaOH, pH 12) of DPP1 (40 µM) or DPP2 (20 µM) was titrated with small aliquots of HCl. 
At least 30 spectra were recorded in the range of pH 2 - 10. Similarly, a solution containing 
DPP2 (20 µM) and CuCl2 in a ratio of 2:1 was titrated with small additions of HCl and at least 
30 spectra were recorded over the range of pH 2 - 7. The acidity and stability constants were 
calculated by using the HypSpec program (Protonic Software, UK).[40] Speciation diagrams for 
DPP1, DPP2, and Cu2+–DPP2 complexes were modeled using the HySS2009 program (Protonic 
Software).[41] 
Metal Binding Studies. The interaction of DPP1 and DPP2 with Cu2+ and Zn2+ was determined 
by UV-Vis and 1H NMR spectroscopy, respectively, based on previously reported 
procedures.[30,42] A solution of ligand (20 µM in EtOH) was prepared, treated with 1 to 20 
equiv of CuCl2, and incubated at room temperature for 2.5 h (for DPP1) or 5 min (for DPP2). 
The optical spectra of the resulting solutions were measured by UV-Vis. The interaction of 
DPP1 or DPP2 with ZnCl2 was observed by 1H NMR. ZnCl2 (1 equiv) was added to a solution 
of DPP1 or DPP2 (4 mM) in CD3CN. The metal selectivity of both compounds was investigated 
by measuring the optical changes upon addition of 1 equiv of CuCl2 to a solution of ligand 
(DPP1 = 40 µM; DPP2 = 20 µM in EtOH) containing 1 equiv or 25 equiv of a divalent metal 
chloride salt (MgCl2, CaCl2, MnCl2, FeCl2, CoCl2, NiCl2, or ZnCl2). The Fe2+ samples were 
prepared anaerobically (all solutions were purged with N2). Quantification of the metal 
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selectivity was calculated by comparing and normalizing the absorption values of metal-ligand 
complexes at λ = 360 nm (for DPP1) or 580 nm (for DPP2) to the absorption at this wavelength 
before and after the addition of CuCl2 (AM/ACu). Cu2+ binding of DPP2 in the presence of Aβ 
was examined by UV-Vis. Aβ (25 µM) was treated with CuCl2 (25 µM) in 20 mM HEPES (2-[4-
(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), pH 6.6, 150 mM NaCl for 2 min at room 
temperature. DPP2 (50 µM) was added to the resulting solution, followed by 4 h incubation. For 
comparison, the optical spectra of DPP2 (50 µM) were measured in the absence and presence of 
CuCl2 (25 µM; 4 h incubation) without Aβ at pH 6.6. 
Aβ  Interaction of DPP1 and DPP2 by Mass Spectrometry. The interaction of DPP1 or DPP2 
with Aβ1-40 was investigated by nano-electrospray ionization-mass spectrometry (nESI-MS) that 
was carried out on a Synapt G2 quadrupole-ion mobility-mass spectrometry system. Samples 
were prepared by mixing stock solutions of DPP1 or DPP2 (prepared in DMSO) and Aβ1–40 
(dissolved in 100 mM ammonium acetate, pH 6.8) to generate desired final concentrations of the 
peptide and the compound. Mixtures were incubated on ice or at room temperature for 2 or 4 h, 
respectively and then analyzed. To produce protein complex ions, an aliquot of the sample (ca. 5 
µL) was sprayed from the nESI emitter using a capillary voltage of 1.4 kV, with the source 
operating in positive ion mode and the sample cone operated at 50 V. In order to normalize 
nESI-MS data for non-specific and electrospray artifact interactions which could occur at high 
concentrations, data were acquired for Aβ samples containing thioflavin-T (ThT), a compound 
known to have no affinity for soluble forms of the Aβ peptide, under identical concentration 
conditions as our DPP1 and DPP2 experiments. Any ThT binding observed was assumed to be 
due to either non-specific binding or the electrospray process, and subtracted from the intensities 
of the DPP1 and DPP2 interactions observed.[43] This procedure was performed over a broad 
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range of concentrations. The mass spectra were acquired with the following settings and tuned to 
avoid ion activation and to preserve non-covalent protein–ligand complexes:[44] backing 
pressure, 7.3 mbar; IMS pressure reading, 3.09 mbar; ToF analyzer pressure, 1.14 × 10−6 mbar. 
Docking Studies. Flexible ligand docking studies using AutoDock Vina[45] for DPP1 and 
DPP2 were conducted against the Aβ1-40 monomer from the previously determined aqueous 
solution NMR structure (PDB 2LFM).[46] Ten conformations were selected from 20 
conformations within the PDB file (1, 3, 5, 8, 10, 12, 13, 16, 17, and 20). The MMFF94 energy 
minimization in ChemBio3D Ultra 11.0 was used to optimize the structures of the ligands for the 
docking studies. The structural files of DPP1, DPP2, and the peptide were generated by 
AutoDock Tools and imported into PyRx, which was used to run AutoDock Vina. The search 
space dimensions were set to contain the entire peptide. The exhaustiveness for the docking runs 
was set at 1024. Docked poses of the ligands were visualized with Aβ using Pymol. 
Amyloid-β  (Aβ) Peptide Experiments. Aβ1-40 was used in all Aβ experiments. Aβ1-40 peptide 
(1 mg) was dissolved with ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, 
and stored at -80 °C. A stock solution (ca. 200 µM) was prepared by redissolving Aβ with 
NH4OH (1% v/v, aq, 10 µL) followed by dilution with ddH2O. All Aβ solutions were prepared 
following previously reported procedures.[29,30] The buffered solutions (20 µM HEPES, pH 6.6 
(for Cu2+ samples) or pH 7.4 (for metal-free and Zn2+ samples), 150 µM NaCl) were used for 
both inhibition and disaggregation studies. For the inhibition experiment, Aβ (25 µM) was first 
treated with a metal chloride salt (CuCl2 or ZnCl2, 25 µM) for 2 min followed by addition of a 
compound (DPP1 or DPP2, 50 µM in DMSO, 1% v/v final DMSO concentration). The resulting 
samples were incubated at 37 °C for 4, 8, or 24 h with constant agitation. For the disaggregation 
experiment, Aβ and a metal chloride salt (CuCl2 or ZnCl2) were initially incubated at 37 °C for 
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24 h with steady agitation. The compound was added afterwards followed by additional 4, 8, or 
24 h incubation at 37 °C with constant agitation. 
Native Gel Electrophoresis/Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) with Western Blotting. The Aβ peptide experiments (as described above) were 
analyzed by both native gel electrophoresis and SDS-PAGE with Western blotting using an anti-
Aβ antibody (6E10).[29,30] Each sample containing 25 µM Aβ  (10 µL) was separated using 
either a 10 - 20% gradient Tris-tricine gel (Invitrogen) or SDS gel (4% stacking gel; 10% 
resolving gel; non-reducing conditions). The gel was transferred to a nitrocellulose membrane 
and blocked overnight with bovine serum albumin (BSA, Sigma, 3% w/v) dissolved in Tris-
buffered saline (TBS, Fisher) containing 0.1% Tween-20 (TBS-T, Sigma). The membrane was 
treated with 6E10 (1:2,000; 2% BSA in TBS-T, Covance, Princeton, NJ) for 4 h at room 
temperature. The membrane was probed with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5,000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in TBS-T 
solution for 1 h at room temperature. The protein bands were visualized using the Thermo 
Scientific Supersignal West Pico Chemiluminescent Subtrate. 
Transmission Electron Microscopy (TEM). Samples for TEM were prepared following a 
previously reported method.[29,30,47] Glow-discharged grids (Formar/Carbon 300-mesh, 
Electron Microscopy Sciences, Hatfield, PA) were treated with samples from either inhibition or 
disaggregation experiments (5 µL) for 2 min at room temperature. Excess sample was removed 
with filter paper and washed with ddH2O five times. Each grid was stained with uranyl acetate 
(1% w/v, ddH2O, 5 µL) for 1 min. Uranyl acetate was blotted off and grids were dried for 15 min 
at room temperature. Images of samples were taken by a Philips CM-100 transmission electron 
microscope (80 kV, 25,000x magnification). 
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Cytotoxicity (MTT Assay). The murine neuro-2a (N2a) neuroblastoma cell line was purchased 
from the American Type Culture Collection (ATCC, Manassas, VA). The cell line was 
maintained in media containing 45% Dulbecco’s modified Eagle’s medium (DMEM) and 50% 
OPTI-MEM (GIBCO), supplemented with 5% fetal bovine serum (FBS, Sigma), 2 mM 
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO). The cells were grown 
and maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability upon treatment 
of compounds was determined using the MTT assay (Sigma Aldrich). N2a cells were seeded in a 
96 well plate (15,000 cells in 100 µL per well) and treated with various concentrations of DPP1 
and DPP2 (2.5 - 50 µM, final 1% v/v DMSO). After 24 h incubation at 37 °C, 25 µL MTT (5 
mg/mL in phosphate buffered saline, PBS, GIBCO, pH 7.4) was added to each well and the 
plates were incubated for 4 h at 37 °C. Formazan produced by the cells was dissolved by 
addition of a solution (100 µL) containing N,N-dimethylformamide (DMF, 50% v/v, aq, pH 4.5) 
and sodium dodecyl sulfate (SDS, 20% w/v) overnight at room temperature. A microplate reader 
was used to measure the absorbance (A600).  
 
Results and Discussion 
Design Consideration, Preparation, and Characterization of Diphenylpropynone 
Derivatives for Targeting and Modulating Metal–Aβ  Species.  
 
A triple bond in the diphenylpropynone scaffold, which has been reported as an Aβ 
imaging probe (Figure 2.1), was shown to have high binding affinity for the β-sheet secondary 
structure of Aβ fibrils due to its rigidity.[48] Based on the incorporation approach, a nitrogen 
donor atom was installed into this framework to generate a metal chelation site with an oxygen 
donor atom of the carbonyl group, which afforded two bifunctional molecules (DPP1 and DPP2, 
Figure 2.1). Furthermore, a minor structural difference (i.e., a dimethylamino functionality, 
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suggested to be critical for Aβ interaction),[30,32,49] could help elucidate a structure-reactivity 
relationship. DPP1 was synthesized as previously established.[34-36] The new compound, 
DPP2, was prepared by slight modifications to a previously reported method (Scheme 2.1).[36]  
In order to predict potential applications of DPP1 and DPP2 in the brain, values of 
Lipinski’s rules and logBB, theoretical measures of blood-brain barrier (BBB) penetration, were 
calculated.[7,50,51] To verify this prediction, an in vitro parallel artificial membrane 
permeability assay adapted for BBB (PAMPA-BBB) was performed.[30] Permeability values (–
logPe) were measured to be 4.2 (±0.1) for both DPP1 and DPP2. Based on empirical 
classification of BBB-permeable molecules (i.e., verapamil),[30] DPP1 and DPP2 would also be 
likely to cross the BBB. 
Scheme 2.1. Synthesis of DPP2. 
 
 
Studies to determine the solution speciation of DPP1 and DPP2, UV-Visible (UV-Vis) 
variable-pH titration experiments (I = 0.10 M NaCl) were conducted at room temperature from 
pH 2.0 to 10.[28,30] An acidity constant (pKa) for DPP1 (pKa = 2.035(5)) and two pKa values for 
DPP2 (pKa1 = 7.106(1) and pKa2 = 2.959(4)) were obtained, indicating the generation of a 
monoprotonated (HDPP1+) and diprotonated species (H2DPP2), respectively (Figure 2.2). Based 
on these data, the generated solution speciation diagrams of DPP1 and DPP2 suggest that at 
physiologically relevant pH (i.e., 7.4), their neutral forms, which may more easily penetrate the 
BBB, are relatively predominant (DPP1, 100%; DPP2, ca. 65%). 
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Figure 2.2. Solution speciation studies of DPP1 and DPP2. Top: UV-Vis spectra of DPP1 (40 
µM, left) and DPP2 (20 µM, right) in the range of pH 2 - 10. Middle: Solution speciation 
diagrams for DPP1 (left) and DPP2 (right) (FL = fraction of compound with given protonation). 
Bottom: Acidity constants (pKa) of L (L = DPP1 or DPP2). Charges are omitted for clarity. a 
Error is shown in the last digit.  Conditions: I = 0.10 M NaCl; room temperature. 
 
Metal Binding Properties of DPP1 and DPP2 
Metal binding properties of DPP1 and DPP2 (specifically, Cu2+ and Zn2+) were studied using 
UV-Vis and nuclear magnetic resonance (NMR) spectroscopy. Upon the addition of CuCl2 (1 - 
20 equiv) to a solution of DPP1 and DPP2 in EtOH, new optical bands were observed indicating 
Cu2+ binding to the ligand (Figure 2.3b). In particular, in the presence of Cu2+, DPP2, which has 
a dimethylamino group, showed a distinguishable optical shift from 407 to 525 nm. NMR was 
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employed to investigate Zn2+ binding to the ligand in detail. When 1 equiv of ZnCl2 was 
introduced in a solution of DPP1 or DPP2 (CD3CN), noticeable downfield chemical shifts of the 
pyridyl protons were recorded (Figure 2.3c), demonstrating that Zn2+ binding to the ligand 
occurred through the pyridyl N-donor atom. 
 
 
 
Figure 2.3. Interaction of DPP1 and DPP2 with Cu2+ and Zn2+. (a) Assigned chemical 
structures of DPP1 (left) and DPP2 (right) (b) UV-Vis spectra of DPP1 (left) and DPP2 (right) 
with CuCl2 (1 - 20 equiv) in EtOH at room temperature (incubation for 2.5 h (for DPP1) and 5 
min (for DPP2)). (c) 1H NMR spectra of DPP1 (black) or DPP2 (black) with ZnCl2 (red) in 
CD3CN at room temperature ([compound] = 4 mM; [ZnCl2] = 4 mM). 
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To obtain binding stoichiometry and approximate binding affinity, solution speciation of 
the Cu2+–DPP2 complex was also studied (1:2 [Cu2+]/[DPP2]; I = 0.10 M NaCl, room 
temperature) through UV-Vis variable-pH titration experiments. Based on the pKa values of 
DPP2 and these titration data, stability constants for the Cu2+–DPP2 complexes were obtained 
(Figure 2.4, M + LH  M(LH) (logβ1 = 12.99(9)); M + L  ML (logβ2 = 5.85(3)); M = 
Cu2+, L = DPP2). A solution speciation diagram was generated from these stability constants, 
suggesting that the major species at pH 7 are a mixture of Cu(LH) and CuL complexes in a ratio 
of 3:2. Free Cu2+ was indicated up to pH 7, showing pCu = 6.6 at pH 6.6 (pCu = 
−log[Cuunchelated]) (Figure 2.4),[28,30,52] which suggests the approximate dissociation constant 
(Kd) of Cu2+–DPP2 to be ca. high nanomolar. When compared to the reported Kd values of Cu2+–
Aβ (picomolar to nanomolar),[2,7,8,14] DPP2 may interact with Cu2+ from soluble Cu2+–Aβ 
species.  
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Figure 2.4. Solution speciation investigation of the Cu2+–DPP2 complex. Top left: UV-Vis 
spectra (pH 2 - 7) for the Cu2+–DPP2 complexes. ([Cu2+]/[L] = 1:2; [Cu2+]total = 10 µM; 7 h 
incubation with ligand (L), L = DPP2; room temperature). Top right: Solution speciation 
diagram of the Cu2+–DPP2 complexes (FCu = fraction of free Cu and Cu complexes). Bottom: 
Stability constants (logβ) of the Cu2+–DPP2 complexes. Charges are omitted for clarity. a Error 
is shown in the last digit. b The species containing CuL2 was introduced into the calculation 
model yielding a good fit to the data. 
 
In order to test Cu2+ binding of DPP2 in the presence of Aβ species (Figure A.1), DPP2 
was added to the solution of Aβ pre-incubated with 1 equiv of CuCl2. The new spectral features 
coincided with those of the Cu2+–DPP2 complex without Aβ (Figure A.1). In the presence of 
Aβ, the binding of DPP2 to Cu2+ occurred more slowly, proposing that Aβ could interfere with 
metal binding to the ligand. Taken together, our spectroscopic studies present the capability of 
DPP1 and DPP2 to chelate Cu2+ and Zn2+, as well as the potential interaction of DPP2 with Cu2+ 
in the presence of Aβ species, which may be associated with reactivity toward metal–Aβ species 
(vide infra). 
The metal selectivity of DPP1 and DPP2 was also investigated by competitive reactions 
with Cu2+ over biologically relevant divalent metal ions (Mg2+, Ca2+, Mn2+, Fe2+, Co2+, Ni2+, and 
Zn2+), monitored by UV-Vis. As depicted in Figure A.2, DPP1 and DPP2 displayed selectivity 
for Cu2+ over Mg2+, Ca2+, Mn2+, and Zn2+. Binding of both ligands to Co2+ and Ni2+ was, 
however, also observed. Considering the lower abundance of Co2+ and Ni2+ than Cu2+ in 
biological systems,[53,54] the overall metal selectivity of DPP1 and DPP2 may be sufficient to 
be used for targeting and interacting with Cu2+–Aβ species in heterogeneous environments like 
the brain.  
Aβ  Interaction with DPP1 and DPP2 Investigated by MS and Docking Studies 
The interaction of DPP1 and DPP2 with Aβ1–40 in the absence of metals ions was probed 
by electrospray ionization-mass spectrometry (ESI-MS), tuned to preserve non-covalent protein–
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ligand interactions.[43] At a low Aβ concentration (10 µM), a small signal corresponding to the 
interaction between DPP2 (30 µM) and the Aβ monomer in the 3+ charge state could be 
detected, while no interaction between DPP1 (60 µM) and the peptide was observed under these 
conditions (Figure A.3). At high concentrations of the peptide (100 µM) and compounds (600 
µM), both DPP1 and DPP2 interacted with Aβ species to different extents (Figure 2.5a). Data 
for DPP1 indicated that the molecule interacted broadly with Aβ monomers and oligomers in 
1:1, 2:1, and 3:1 Aβ to ligand ratios. In the case of DPP2, a stronger preference toward larger Aβ 
oligomers was shown, but with similar stoichiometries as DPP1. The total bound intensities 
recorded from MS data, and those from individual oligomeric species were shown in Figure 2.6b 
and Table 2.1. The intensities shown were normalized for both non-specific interactions and 
artifactual complexes formed during the electrospray process using Aβ:thioflavin-T binding data 
as a control, and ion mobility separation was used to separate oligomers that overlapped in 
m/z.[6,43,55] From these data, it was clear that, at high concentrations, a higher proportion of 
DPP1 was bound to Aβ species than DPP2, but that both could be classified as having weak Aβ 
affinity in solution (low mM Kd). Therefore, a weak Aβ/compound interaction was captured by 
MS. Normalized intensity MS data suggest that DPP2 binding was almost exclusively driven 
through Aβ multimer interactions (Figure 2.5b). Overall, our MS results suggest that while both 
compounds could interact with Aβ species at high concentrations, DPP2 was able to bind Aβ 
species at both low and high concentrations. 
 In order to visualize the potential interaction between Aβ and DPP1/DPP2, docking 
studies by AutoDock Vina were performed using the previously determined NMR structure 
(PDB 2LFM) of Aβ1-40 monomer.[45,46] Typically, both compounds were positioned between 
the α-helix and the unstructured N-terminal side of Aβ (Figures 2.5c and Figure A.4). Most 
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docked structures showed a non-specific orientation of the ligand with respect to the surface 
features of Aβ. Our preliminary docking studies support the interaction of the compounds with 
Aβ monomer, observed by MS. 
             
 
 
Figure 2.5. Interactions of DPP1 and DPP2 with Aβ species. (a) MS data for Aβ1-
40:DPP1/DPP2 complexes ([Aβ] = 100 µM; [compound] = 600 µM; M = monomer, D = dimer, 
and T = trimer). Many binding stoichiometries were detected, including 1:1 (star), 2:1 (square), 
and 3:1 (triangle). (b) A histogram showing the total bound MS signal intensity, normalized for 
non-specific interactions and ESI-MS artifacts, for each binding stoichiometry observed in (a). 
(c) Docking studies of DPP1 (orange) and DPP2 (green) with Aβ1-40 (PDB 2LFM) by AutoDock 
Vina. Poses for both compounds were overlapped in this conformation (other conformations, 
Figure A.4). The helical region of Aβ (H13 - D23) is highlighted in color (tan) in both the 
cartoon (left) and surface (right) representations.  
 
Effects of DPP1 and DPP2 on Metal-free and Metal-induced Aβ  In Vitro 
Confirming metal binding and Aβ interaction properties (bifunctionality) of DPP1 and DPP2, 
their influence on of metal-free and metal-induced Aβ aggregation were studied in vitro.[27-33] 
To investigate if DPP1/DPP2 can control the formation of metal-free and metal-induced Aβ 
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aggregates or transform preformed metal-free and metal-induced Aβ aggregates, inhibition 
(Figure 2.6) and disaggregation experiments (Figure A.5) were conducted. The visualization of 
various-sized Aβ species from both inhibition and disaggregation studies were carried out by 
native gel electrophoresis and SDS-PAGE followed by Western blotting with an anti-Aβ 
antibody (6E10), while morphological changes were identified by transmission electron 
microscopy (TEM).[27-32]  
In the inhibition studies, different reactivity of DPP1 or DPP2 toward metal-induced Aβ 
species over metal-free Aβ species was observed. In the case of metal-involved Aβ aggregation, 
Aβ species with a wide range of MW were indicated with DPP2 for both Cu2+- and Zn2+-treated 
samples upon longer incubation (Figure 2.6a, lanes 6 and 9). In the samples containing DPP1 
(lanes 5 and 8), less intense gel bands were detected across the longer incubation time, 
suggesting that further Aβ aggregation may have occurred. The reaction of DPP1 or DPP2 with 
metal-free Aβ also exhibited a different distribution of various-sized Aβ species (Figure 2.6a, 
lanes 2 and 3). Aβ species formed with compounds in both metal-mediated and metal-free 
conditions were not completely denatured by SDS implying that these molecules may generate 
different Aβ assemblies (Figure 2.6b). TEM images of metal-induced Aβ species incubated with 
DPP2 for 24 h revealed smaller amorphous aggregates compared to DPP1; some of the metal-
free Aβ species treated with DPP1 and DPP2 presented similar morphology to those untreated 
with compounds (Figure 2.6c). Overall, DPP1 and DPP2 displayed the ability to recognizably 
modulate metal-induced Aβ aggregation to different extents. 
Furthermore, for the disaggregation studies, in metal-mediated conditions, DPP2- treated 
metal-triggered Aβ aggregates presented different-sized Aβ species than DPP1-treated samples, 
indicating that DPP2 could alter the properties of preformed Aβ aggregates to a greater extent 
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than DPP1 (Figure A.5a). In the metal-free conditions, more various-sized Aβ species were 
indicated in the presence of DPP2 than DPP1 (in particular, at 4 h, Figure A.5a, lanes 2 and 3). 
The Aβ species generated with compounds in both metal-triggered and metal-free conditions 
were relatively stable in the presence of SDS (Figure A.5b). As shown in Figure A.5c, DPP2 was 
able to reorganize preformed structured metal-Aβ aggregates to amorphous species more 
noticeably than DPP1. Taken together, the results from both the inhibition and disaggregation 
experiments presented that DPP1 and DPP2 could regulate metal-involved Aβ aggregation over 
metal-free aggregation in vitro differently. Moreover, the structural variation (i.e., 
dimethylamino functionality) was shown to possibly differentiate the reactivity with metal–
Aβ species. 
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Figure 2.6. Inhibition experiment (scheme, top). Analysis of various-sized Aβ species by (a) 
native gel electrophoresis and (b) SDS-PAGE (non-reducing conditions) with Western blot. (c) 
TEM images of the 24 h incubated samples. Conditions: [Aβ] = 25 µM; [CuCl2 or ZnCl2] = 25 
µM; [compound] = 50 µM; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 
4, 8, or 24 h incubation; 37 °C; constant agitation. 
 
Summary and Perspective 
Following the incorporation approach, we have developed bifunctional small molecules 
(DPP1 and DPP2) composed of a metal chelation site and a diphenylpropynone framework (for 
Aβ interaction), which could possibly serve as chemical reagents to target and modulate metal–
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Aβ species in vitro. Their bifunctionality (metal chelation and Aβ interaction) was confirmed by 
physical methods and preliminary docking studies. Biochemical and TEM studies revealed that 
DPP1 and DPP2 could modulate metal-induced Aβ aggregation in vitro. Notably, DPP2, which 
has a dimethylamino group, exhibited more apparent reactivity toward metal–Aβ species, 
compared to DPP1. This suggests that the interaction and reactivity of molecules with metal–Aβ 
species can be tuned by such structural variations (a structure-interaction-reactivity relationship). 
DPP1 and DPP2, however, would be limited in their biological applications since they displayed 
cytotoxicity in living cells at low micromolar concentrations (Figure A.6). Overall, the promising 
in vitro reactivity of these potentially BBB-permeable molecules toward metal–Aβ species 
warrants pursuit of structural modifications that would improve the viability of 
diphenylpropynone derivatives in biological settings, followed by more detailed characterization 
by MS and molecular modeling. This study has demonstrated the capability of two 
diphenylpropynone derivatives to target and modulate the reactivity of metal-Aβ species, which 
can be further optimized toward the development of future chemical reagents and therapeutics 
for AD. 
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Chapter 3: Influence of a Curcumin Derivative on hIAPP Aggregation in the 
Absence and Presence of Membrane Lipids 
This chapter was adapted from the following publication:  
Pithadia, A. S.; Bhunia, A.; Sribalan, R.; Tamilenthi, P*.; Fierke, C. A.; Ramamoorthy, A. 
Chem. Commun. 2015. 10.1039/c5cc07792c.III 
 
*CurDAc was provided by Padmini Tamilenthi 
 
3.1. Introduction 
Human islet amyloid polypeptide (hIAPP) or amylin, is a 37 residue peptide hormone 
secreted from β-cells within the islet of Langerhans in the pancreas. hIAPP has received much 
attention due to its possible involvement in the pathology of diabetes mellitus, or type-II 
diabetes.[1,2] The protein found in islet cell deposits was characterized as IAPP and further 
confirmed the deposits as amyloid fibers,[3] a particular form of misfolded proteins which adopt 
a cross-β sheet structure with each monomer in the fibril adopting a β-sheet structure. More 
careful analysis indicated that β-cell mass is reduced strongly in islets containing IAPP deposits 
suggesting a possible toxic effect of IAPP on β-cells due to intermediary species (e.g., 
oligomers) generated during amyloid fibril assembly. A well-studied mechanism of toxicity by 
IAPP is the disruption of cellular (plasma and organelle) membranes.[4] These disruption events 
are suggested to happen through pore-like and   fragmentation mechanisms which compromise 
the integrity of the lipid bilayer.[5-9]  
                                                
IIIASP – biophysical studies; AB – NMR; RS and PT – synthesis of CurDAc 
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A method to probe the inhibition of aggregation as well as rescue membrane integrity has 
been through the employment of small molecules.[10-12] These chemical modulators could 
stabilize the monomer thus blocking the formation of toxic oligomers, divert the monomeric 
peptide to off-pathway non-toxic intermediates, prevent the primary nucleation process by 
destabilizing oligomers, or destabilize fibrils to form monomers or non-toxic oligomers. 
Specifically, natural products make a promising class of viable candidates as small molecule 
inhibitors of amyloids.[13-17] Curcumin, a natural product found abundantly in turmeric that is 
used in most south Asian spices, has been widely categorized as having therapeutic properties 
due to its antioxidant, anti-cancer, antibiotic and anti-amyloidogenic properties.[18] It has been 
shown to non-specifically bind to amyloid-β monomers and fibrils and modify the protein 
aggregation pathway;[18-21] but less is known about the interactions between curcumin and 
hIAPP. Curcumin has demonstrated inhibitory properties against hIAPP; however, its 
mechanism of action still remains elusive.[22,23] Many recent studies have focused on the anti-
amyloidogenic, properties, but limited utility of curcumin, thus leading to the generation of 
rationally designed curcumin analogues and derivatives which have demonstrated to have 
increased stability and solubility compared to curcumin while showing very promising activity 
against amyloid proteins both in vitro and in vivo.[24-28] 
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Figure 3.1. Chemical structures of curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-
methoxyphenyl)hepta-1,6-diene-3,5-dione) and CurDAc (sodium 2,2'-((((1E,6E)-3,5-
dioxohepta-1,6-diene-1,7-           diyl)bis(2-methoxy-4,1-phenylene))bis(oxy))diacetate). The 
hydroxyl moieties are modified to acetates. 
 
Herein, we present a curcumin derivative, curcumin diacetate (CurDAc) (Figure 3.1) 
which exhibits increased stability and solubility in aqueous conditions, as an ideal small 
molecule candidate to study against IAPP aggregation and membrane stability. Our results 
demonstrate that this derivative has the propensity to modulate amyloid aggregation through an 
inhibition mechanism in the presence and absence of biological membrane mimics, unlike the 
results seen for this molecule with 
Aβ, which did not have a substantial influence on Aβ aggregation.[24] CurDAc serves as a 
template to modify curcuminoids which can help toward developing therapeutic compounds for 
modulating hIAPP aggregation and rescuing membrane integrity thus greatly reducing IAPP-
induced toxicity. Biophysical characterization has helped us evaluate the effects of the curcumin 
derivative, CurDAc on an inhibitory mechanism of mature IAPP fibril formation.[29] 
MATERIALS AND METHODS 
Vanillin, 2,4-pentadione and n-butylamine were purchased from Sigma Aldrich. Tri-n-butyl 
borate was purchased from Alfa Aesar. All compounds were used without further purification. 
NMR characterizations for synthetic intermediates and CurDAc were performed using a Bruker 
Avance 300 MHz spectrometer. Mass spectra were recorded on a LCQ Fleet Mass Spectrometer 
(Thermo-Fisher Ltd., U.S.A.) 
Scheme 3.1: Synthesis of CurDAc 
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Synthetic procedure for 2-(4-formyl-2-methoxyphenoxy)acetic acid (2):[24]  
The vanillin (1.0g, 0.0065 mol) was dissolved in 1 N NaOH (16 mL) solution.  The solution was 
refluxed with chloroacetic acid (0.68g, 0.0072 mol) for 12 hrs.  Then the reaction mixture was 
diluted with water (10 mL) washed with ethyl acetate (2 x 25 mL), then the aqueous layer was 
separated and acidified with conc HCl.  Then the mixture was extracted with ethyl acetate (3 x 
50 mL) (in the ethyl acetate layer the product was dissolved along with unreacted vanillin).  The 
combined organic layers were extracted with saturated sodium bicarbonate solution (2 x 50 mL) 
and separated.  The sodium bicarbonate solution was acidified with conc. HCl which gave the 
product as a white precipitate.  The product was subsequently filtered and dried in hot air oven at 
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Reagent Conditions: (i) ClCH2COOH; 1 N NaOH; H2O; reflux, 12 h. (ii) 2,4-pentadione; boron oxide; 
tri n-butyl borate; n-butylamine; DMF; 70 OC, 4 h. (iii) ACN, 1 N NaOH, 0 OC, 5 min. 
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60 °C for 24 hrs (yield: 86.2%). 1H NMR (300 MHz, CDCl3) δ 9.86 (s, 1H), 7.44 – 7.42 (m, 2H), 
6.92 (d, J = 8.7 Hz, 1H), 4.76 (s, 2H), 3.95 (s, 3H). 13C NMR (75 MHz, CDCl3+DMSO-D6) δ 
190.52, 169.57, 152.52, 130.57, 125.77, 112.14, 109.79, 65.39, 55.74. ESI-MS calculated. m/z 
210.04. found 209.03 (M--1). 
Synthetic procedure for 2,2'-((((1E,6E)-3,5-dioxohepta-1,6-diene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))diacetic acid (3): 
To a 2,4-pentadione (0.099 mL, 0.95 mmol), boron oxide (0.065 g, 0.95 mmol), tri-n-butyl 
borate (0.50 mL, 1.89 mmol) and vanillin acetic acid (0.4g, 1.89 mmol) were added.  The 
mixture was dissolved in dimethylformamide (2 mL) and heated to 70 °C. When the reaction 
temperature reaches 70 °C, n-butylamine (0.096 mL, 0.95 mmol) was added drop wise over 5 
min.  Then the reaction mixture was stirred at 70 °C for 4 hrs.  Then the reaction mixture was 
added to 5% hot acetic acid solution (4 mL) and stirred for 3 hrs.  It was diluted with water (25 
mL) and extracted with ethyl acetate (2 x 50 mL).  The combined organic layers were again 
washed with water (50 mL) and extracted with 10% sodium bicarbonate solution (2 x 25 mL).  
The aqueous layer was separated and neutralized with 2 N HCl (the pH of the solution should be 
6.0-6.5).  The yellow precipitate obtained was filtered and dried in vacuum.  The filtered solid 
was washed with ethyl acetate afforded product 3 as a yellow solid (yield: 62.5%). 1H NMR (300 
MHz, DMSO-D6) δ 7.64 (d, J = 15.6 Hz, 2H), 7.43 (s, 2H), 7.29 (d, J = 7.8 Hz, 2H), 7.96 – 6.86 
(m, 4H), 6.18 (s, 1H), 4.79 (s, 4H), 3.90 (s, 6H). ESI-MS calculated. m/z 484.14. found 485.04 
(M++1). 
Synthetic procedure for sodium 2,2'-((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(2-methoxy-4,1-phenylene))bis(oxy))diacetate (CurDAc) 
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The compound 3 (0.1 g, 0.20 mmol) was taken in the round bottom flask and cooled to 0 °C. To 
that solid 1 N NaOH (0.413 mL) was added and stirred for 5 min at 0 °C. Then to that solution 
acetonitrile (3mL) was added, the precipitate was obtained as the free acid. The product was 
filtered and dried in vacuum to give the sodium salt as a reddish brown solid (yield: 90.1%). 1H 
NMR (300 MHz, D2O) δ 7.13 (d, J = 15.8 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 6.81 (s, 2H), 6.57 
(d, J = 8.0 Hz, 2H), 6.24 (d, J = 15.8 Hz, 2H), 4.29 (s, 4H), 3.74 (s, 6H). ESI-MS calculated. m/z 
528.10. found 529.25 (M++1). 
Peptide Preparation. To remove preformed aggregates, hIAPP was dissolved in 
hexafluoroisopropanol (HFIP) followed by removal of the solvent by lyophilization for 48 hours 
in aliquots of either 0.1 - 0.3 mg. The peptide aliquots were then stored at -20 ᴼC. hIAPP 
monomer sample was prepared by dissolving the lyophilized peptide in chilled, dilute HCl (pH 
4) to stock concentration between 150 – 200 µM,  kept at 0 ᴼC (ice), vortexed for 15 s. and bath 
sonicated (at 0 ᴼC) for 1 min. Fresh hIAPP monomer samples were diluted into the appropriate 
buffer for each subsequent experiment.  
Bicelle and Vesicle Preparation: All lipids were purchased from Avanti Polar Lipids 
(Alabaster, AL).  DMPC/DHPC (2:1) bicelles were prepared by lypholizing the lipid film 
overnight. Lipids were rehydrated in phosphate buffered saline (10 mM, 100 mM NaCl, pH 7.4) 
and vortexed at 4 ᴼC until lipids were completely dissolved. Lipid solutions underwent five 
freeze-thaw cycles to generate bicelles. Lipid vesicles were prepared by rehydration and micro-
extrusion through a 100 nm membrane 21 times. Vesicles were measured by dynamic light 
scattering (DLS) to confirm their size (data not shown). Dye-filled vesicles were prepared at 10 
mg/mL in a similar fashion, however rehydrated with a 6-carboxyfluorescein solution. After 
extrusion, dye-filled vesicles were separated on a size-exclusion column (GE Sephadex G50) to 
 55 
remove any free carboxyfluorescein. The concentration of dye-filled vesicles was measured 
using the Stewart assay. 
Thioflavin T (ThT) Fluorescence Assays.  ThT fibril formation was measured by increased 
fluorescence emission upon binding of amyloid fibers to the commonly used amyloid-specific 
dye, ThT. ThT was added to a chilled phosphate buffered saline (10 mM phosphate, 100 mM 
NaCl, pH 7.4) to make a final dye concentration of 20 µM. For experiments without lipids, 
CurDAc (10 mM) was added. To solutions containing bicelles and vesicles, lipids were added to 
a final concentration of 100 - 1000 µM. hIAPP monomer solution was added to each well to a 
final peptide concentration of 10 µM. Fluorescence emission was measured in microplate 
formate on a BioTek Synergy 2 microplate spectrofluorometer using excitation and emission 
wavelengths of 440 and 480 nm, respectively.  
Dye Leakage Fluorescence Assay: POPC/POPG (7:3) vesicles were prepared with 6-
carboxyfluorescein as describe above. The final concentration of dye-filled vesicles used in each 
experiment was 0.2 mg/mL. Vesicles were added to a solution of PBS (10 mM, 100 mM NaCl, 
pH 7.4) and to this CurDAc (10 µM) was added. An initial fluorescence scan (λex = 490 nm; λem 
= 520 nm) was taken to ensure no free dye was present in solution. To each well hIAPP (10 µM) 
was then added. After 24 h, vesicles were treated with 0.1% Triton-X to burst the vesicles for the 
maximum fluorescence measurement. Control fluorescence scans (λex = 490 nm) were run in the 
presence of 0.2 mg/mL carboxyfluorescein and 10 µM CurDAc to demonstrate no signal 
overlap between the dye and the small molecule. 
Circular Dichroism (CD). CD measurements were performed on JASCO J-815 
Spectropolarimeter using a 0.1 cm path length cell. Freshly prepared monomer solution was 
added to PBS (10 mM, 100 mM NaF, pH 7.4) at a final concentration of 20 µM. Samples 
 56 
containing CurDAc were co-incubated with 20 mM compound. Molar CD per residue values 
were calculated using ε = θobsd/(3298lcn), where θobsd is the observed ellipticity measured in 
millidegrees, c is the molar concentration, l is the cell path length in centimeters, and n is the 
number of residues in the peptide.   
Dynamic Light Scattering (DLS).  Light scattering experiments were performed on hIAPP (25 
µM) and hIAPP with CurDAc (25 µM) using a DynaPro Nanostar instrument from Wyatt 
Technology (Santa Barbara, CA). Light scattering was measured at 90°. The intensity correlation 
function and the distribution of the hydrodynamic radii (Rhyd) of the particles contributing to the 
scattering were determined using DYNAMICS software (Wyatt Technology). 
Transmission Electron Microscopy (TEM). Samples for negative stain TEM analysis were 
deposited on continuous carbon films on copper rhodium 100 mesh grids (Electron Microscopy 
Sciences, EMS Hatfield PA.). Prior to adding samples, the grids were charged using a glow 
discharger for 15 s at 30 mA negative discharge. Aliquots from ThT experiments incubated for 4 
h were adsorbed to the grids for 2 min prior to rinsing with two 10 µL drops of water for 10 s. 
Samples were blotted using No. 2 Whatman filter paper. Samples for TEM were then stained 
with a 10 µL drop of freshly filtered 2% uranyl acetate (EMS) for 15 s before blotting excess 
stain. Samples were analysed using a Philips CM-100 microscope operating at 80 kV. 
Saturation Transfer Difference Nuclear Magnetic Resonance (STD NMR). Saturation 
transfer difference (STD) NMR experiments for a sample containing CurDAc (250 µM) and 
hIAPP monomers (25 µM) were carried at 25 ºC for 18 hours consecutively with an interval of 
15 min using a Bruker 600 MHz NMR spectrometer equipped with a cryo probe. The peptide, 
hIAPP or its fibril was RF-irradiated at -1 (on-resonance) and at 40 ppm (off-resonance) for a 
duration of 2 s and 128 scans were co-added to get the spectrum. The selective RF-irradiation 
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was achieved by a train of Gaussian pulses with 1% truncation for a duration of 49 ms with an 
interval of 1 ms at 50 dB. 
Results and Discussion 
CurDAc was designed as a water-soluble derivative of curcumin that requires organic 
solvents for solubilization and use in aqueous buffered systems (Figure 3.1).[30] This was 
achieved through the insertion of an acetate moiety that introduces two negative charges on the 
framework at pH > 5 (sodium salt form, Scheme 3.1).[28] A degradation mechanism through the 
autoxidation of curcumin that occurs through the phenolic moieties has been proposed.[31] 
Therefore, by capping these sites, more stable derivatives can be formed, as in the case of 
CurDAc that appends acetate functional groups to diminish this oxidation event. These negative 
charges may also provide a molecular basis for interaction with hIAPP through electrostatic as 
well as hydrogen bonding. The design of a curcumin derivative was of particular interest due to 
the instability of curcumin in aqueous conditions, which has made it increasingly difficult to 
study the activity of the parent structure with amyloid proteins (Figure B.1).[25-27]  
Both the excitation and emission profiles for CurDAc do not interfere with thioflavin-T 
(ThT), thus making it possible to study aggregation through fluorescence.[22] In our 
experimental conditions, hIAPP displayed a lag phase of ~75 min and fully mature fibrils at 
~200 min (Figure 3.2A). In the presence of 1 equiv. CurDAc, a complete inhibition of hIAPP 
aggregation was seen, which is attributed to the stabilization of monomers, or low molecular 
weight (LMW) oligomers that do not consequently form β-sheet rich fibrillar species in the 
presence of a small molecule. To verify this inhibition and at the same time to rule out false 
positives results by fluorescence experiments, 1H STD NMR experiment was employed (Figure 
3.2B). This technique is commonly used to understand ligand-receptor interactions by measuring 
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the magnetization transfer between the receptor (hIAPP), which is irradiated at a specific on-
resonance frequency, and the ligand (CurDAc).[32]  The top spectrum is a standard 1H NMR 
spectrum of CurDAc displaying only the aromatic region of the ligand. The 1H STD spectrum 
displayed no signal when CurDAc was co-incubated with freshly prepared monomers, indicating 
that the ligand, CurDAc, and hIAPP monomers tumble fast in solution due to their low 
molecular weight. Remarkably, no signal was observed even when the experiment was continued 
over 18 h (CurDAc + monomer), suggesting that hIAPP did not exist in its fibrillar form and 
may be stabilized as LMW species through an inhibition mechanism. In contrast, when hIAPP 
fibril was added to the ligand, efficient magnetization transfer from the large-size hIAPP fibrils 
to CurDAc resulted in a strong STD effect, mainly in the aromatic region of the ligand revealing 
interaction of aromatic rings with hIAPP (Figure 3.2B, CurDAc + fibril). These results are also 
in good agreement with microscopy images (Figure B.2). Under the conditions of ThT assay, 
CurDAc induced small, but more amorphous, hIAPP species that may not propagate toward 
toxic higher-order fibrils. 
As shown in Figure 3.3A, circular dichroism (CD) experiments revealed the expected 
random coil to β-sheet conformation transition of hIAPP after 24 h. However, in the presence of 
CurDAc, a more pronounced helical conformation was observed, indicating selective IAPP 
intermediate species stabilized through interactions with the ligand. This may occur through 
charge-charge interaction between CurDAc and hIAPP, which may force the peptide to a 
specific conformation and thus altering its aggregation properties rather than disrupting the helix 
to force IAPP aggregation as reported previously.22 Investigations are on going to decipher if 
CurDAc is reordering the monomer to a helix, or if the small molecule binds to a helical 
conformation, similar to the interactions seen between curcumin and the amyloid protein 
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PrP.[33] This observation is unique to this derivative as studies on curcumin showed the 
instability of the helical intermediate upon incubation.[23] Dynamic light scattering (DLS) 
experiments further confirms the formation of a LMW hIAPP species in solution with CurDAc 
present. Filtered samples of CurDAc and hIAPP at 4 h showed relatively mono disperse 
intensity peaks ~10 nm in hydrodynamic radius (Figure B.3), different from peptide alone 
sample that has a heterogeneous dispersity of large oligomers and protofibrils between 50 and 
100 nm (Figure B.3).  This conformational change could be responsible for the inhibitory 
properties of CurDAc, which does not allow for specific interactions between hIAPP strands that 
are responsible for the formation and growth of fibrils.[34] 
 
 
 
Figure 3.2. Inhibition of hIAPP by CurDAc. A) Thioflavin-T (ThT) fluorescence assay to 
measure the aggregation of hIAPP in the absence (10 µM, black) and presence of 1 equiv. 
CurDAc (10 µM, grey). B) 1H NMR spectra of CurDAc (250 µM) alone (top, blue), 1H STD 
NMR spectra of CurDAc + hIAPP (25 µM) fibril (middle) and CurDAc + hIAPP (25 µM) 
monomer (bottom). At a stoichiometric ratio of CurDAc, a full mitigation of fibrillation was 
observed. The absence of a STD signal in (B) indicates lack of large, slow-tumbling species or 
aggregates. 
 
Inhibitors have the connotation that they mitigate fibril formation from freshly prepared 
monomers in solution; however, identifying some of these compounds as chemical modulators, 
instead of inhibitors is more accurate. The disassembly of hIAPP in solution was also monitored 
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using the ThT assay by adding CurDAc at ~200 min, when a high population of mature β-sheet 
containing fibrils was present (Figure B.4). Upon addition of CurDAc, a gradual loss in the ThT 
fluorescence signal was seen, inferring that the population of mature fibrils was diminishing in 
solution through the disaggregation of hIAPP. A depolymerisation event of α-synuclein has also 
been seen with curcumin-pyrazole derivatives,[21] alluding to the possible broader scope of 
CurDAc for disassembling fibrils of other amyloids. The intensity did not equilibrate to the 
baseline, which may suggest that the small molecule does not disaggregate hIAPP fibers to 
monomers.[16] Taken together, these results suggest that CurDAc has both the ability to halt 
fibril formation from fresh monomers as well as depolymerize preformed fibrils in solution. 
Given the promising results, we wanted to further investigate how CurDAc behaves in 
the presence of lipid membrane to measure its amyloid inhibitory role towards lipid membrane 
protection and stabilization. Studies in the presence of lipid membrane have demonstrated that 
curcumin can interact with the lipid bilayer through two modes: (i) a surface interaction through 
electrostatic interaction with positively charged lipid head groups by H-bonding or (ii) a 
transmembrane insertion that segmentally orders lipid bilayers due to its rigidity.[35] 
We investigated the influence of CurDAc on hIAPP aggregation in the presence of 
model membranes such as bicelles and lipid vesicles. The kinetics of hIAPP aggregation are 
altered in the presence of lipid bilayers due to possible surface level interactions that help 
nucleate monomers and LMW oligomers into fibril formation more quickly (Figure 3.4).[36] 
Though the exact mechanism for the interaction between CurDAc and membrane has not been 
worked out yet, surface adsorption of the small molecule could coat the membrane to disable 
fibrillation at the surface. 
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Figure 3.3. CD measurements indicating a change in peptide secondary structure after 24 h. CD 
spectra of 20 µM hIAPP solution without (A) and with (B) 20 µM CurDAc. A transition from 
random coil to b-sheet in the absence of CurDAc (A) and random coil to a-helix in the presence 
of 20 µM CurDAc (B, grey) was observed after 24 h. CurDAc may stabalize a specific 
monomer conformation or small oligomer assemblies of hIAPP. 
 
Experimental results shown in Figures 3.4A and 3.4B suggest that the fibrillation of 
hIAPP was negligible when CurDAc was incubated with DMPC/DHPC (2:1) bicelles and 
hIAPP or POPC/POPG (7:3) large unilamellar vesicles (LUVs) and hIAPP. These results shed 
insights into molecular frameworks that could be used as membrane-protective agents against 
amyloid-induced cellular toxicity.[37] A surface level or membrane insertion mechanism has 
been considered and further investigated; but a membrane protection occurs with CurDAc as 
seen from dye leakage studies. POPC/POPG vesicles encapsulated with 6-carboxyfluorescein are 
traditionally used to measure membrane permeation through pore-like or detergent-like 
mechanisms.[38] In this case, we see direct membrane fragmentation of the vesicles by hIAPP 
(Figure B.5) [39,40] which are inhibited by the addition of CurDAc.  
In summary, our study demonstrated a curcumin derivative, CurDAc, that can be used in 
stoichiometric amounts to suppress hIAPP fibril formation in solution both in the absence and 
presence of lipid membrane. The adoption of a helical intermediate may be a feature to exploit 
for further atomic-level structural investigations due to its stability over time. Furthermore, the 
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ability of CurDAc to protect lipid membrane may make it a useful scaffold for potential 
therapeutic applications. This small molecule possesses advantageous characteristics compared 
to its natural product counterpart, and further studies toward understanding its high-resolution 
interaction with hIAPP and lipid bilayer should be fruitful. 
 
 
 
Figure 3.4. Thioflavin-T assays of 10 µM hIAPP (A, black) incubated with 2:1 DMPC:DHPC 
bicelles (A) and with CurDAc added (A, grey). B) Aggregation of 10 µM hIAPP in 7:3 
POPC:POPG large unilamellar vesicles (black) and with the addition of CurDAc  (grey). 
Fibrillation is mitigated in both model membrane systems showing full inhibition of fibrillation 
as discussed in the text. 
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Chapter 4: Self Assembly of a 9-Residue Peptide Fragment of SARS Corona Virus 
E-protein:  Mechanism of Self Aggregation and Amyloid-Inhibition of 
hIAPP 
This chapter was adapted from the following publication: 
 
Ghosh, A§.; Pithadia, A. S§.; Bhat, J.; Bera, S.; Midya, A.; Fierke C. A.; Ramamoorthy, A.; 
Bhunia, A. Biochemistry, 2015, 54, 2249.3 
 
§Authors contributed equally to this work.  
 
4.1 Introduction 
The formation of nanostructures through molecular self-assembly has been demonstrated 
to be a ubiquitous process in nature as seen by organic molecules (polymers), proteins, peptides 
and DNA. These nanostructures have been characterized by their highly ordered aggregate 
formation through non-covalent interactions (e.g., electrostatic, hydrogen bonds, van der Waals, 
and aromatic π-stacking and cation-π). The emerging field of nanotechnology has exploited self-
assembly systems due to the key advantage that their physical, chemical, optoelectronic, 
magnetic and mechanical properties are tunable via control of their size and shape.[1]  
Interestingly, all the aforementioned non-covalent forces are quite weak in nature, individually, 
but cumulatively they support the self-organization of simple units into complicated and 
controlled structures.[2] Despite tremendous research efforts, the relative involvement of these 
forces in self-assembly processes is yet to be more clearly understood. Recently, substantial 
                                                
3 AG – synthesis and NMR; ASP – ThT, CD, NMR, writing manuscript; JB and SB – 
simulations; AM - docking 
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attention has been intended for the rational design and structural analysis of peptide based self-
assembly due to their widespread diversity in chemical, structural and functional aspects.[1,3] 
Furthermore, the complex nature of biomolecules limits the comprehensive understanding of the 
factors controlling the self-assembling properties. To examine this in more detail, short peptides 
or peptide fragments can be constructed relatively quickly and may serve as the competent 
building blocks for self-assembled systems thus avoiding the complexities of forming and 
studying large protein structures.  
Self-assembled peptide systems have also been utilized in studying protein-folding events 
in order to provide insight into the thermodynamic properties of protein folding and misfolding. 
These investigations have also helped gain information about specific structural motifs adopted 
by specific amino acid sequences and combinations which may be responsible for protein 
misfolding and amyloid formation. Therefore, studying the self-assembly of peptides has been 
utilized as an important tool for analyzing the local structure (e.g., secondary structure) of 
peptide fragments in the context of the global protein structure.[4] These peptide nanostructures 
are generally formed from beta (β)-sheet motifs, although a few helical-based assemblies have 
also been reported.[5-8] Based on various structural, chemical and physical properties they are 
classified according to the following categories: a) lipid-like peptides, b) surfactant peptides, c) 
amphiphilic peptides, d) aromatic di-peptide motifs, e) cyclodextrin-based polyionic amino acids 
from known self-assembled proteins, e) cyclic peptides and f) arbitrarily chosen peptide 
sequence based on amino acid properties.[9] The unique supramolecular assemblies can be 
readily tuned by modifying structural properties such as changing the amino acid sequence or 
conjugating chemical groups or by varying experimental parameters such as pH or solvent. 
Peptide nanostructures have also been utilized in vast miscellaneous fields, from antibacterial 
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agents to molecular electronics with a great achievement and therefore have become of great 
interest to study.[10, 11]  
Importantly, investigating self-assembly systems at the molecular level have been of 
particular value in studying the complex phenomena behind the aggregation of amyloid proteins 
and aggregation of other proteins related to fatal protein conformational disorders.[12] It has 
been found that amyloid-related diseases (e.g., Alzheimer’s disease (AD), Prion diseases, Type II 
diabetes, Parkinson’s disease, and Huntington’s disease) are connected by the aggregation of 
relatively unstructured monomers into a β-sheet rich fibrillar aggregates.[13,14] In spite of the 
diversity in sequence homology, the fibrillar network have similar morphologies; however, the 
precise biochemical/biophysical pathways and mechanism of protein fibrillation still remain 
elusive. Self-assembled short peptides have the potential to serve as model systems to studying 
amyloid aggregation by simplifying the study of amyloidosis as seen in a study by Lynn and co-
workers.[15] This can help probe specific protein-protein interactions between the small peptide 
assemblies and translate this information to elucidating the aggregation properties of the native 
peptide/protein. Furthermore, small peptide fragments from amyloid proteins (KLVFF in 
amyloid-β and NFGAIL in hIAPP) have demonstrated to have inhibitory properties, thus 
modifying or in some cases halting the aggregation pathway.  Therefore, studying self-assembled 
peptide fragments may also help potentially uncover possible motifs that may be utilized for 
amyloid inhibition and eventually therapeutic applications. 
In the present study, we have investigated and analyzed the self assembly of a 9 residue 
peptide (hereafter denoted as TK9) and its derivatives taken from the sequence of the carboxyl 
terminal (55-63) of SARS Corona Virus Envelope protein (Scheme 4.1).[16] Generally, corona 
viruses are enveloped and this enveloped (E) region may be the main culprit in causing virulence 
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related to various respiratory diseases such as, common colds, bronchiolitis, and acute 
respiratory distress syndrome in humans and other.[17] The E regions are peptide fragments 
consisting of 76-108 amino acids and composed of a flexible region at both N- and C- terminals 
and α-helical transmembrane (TM) region.[18] This region has shown to adopt mainly helical 
structure in the presence of SDS micelles, suggesting that a membrane surface may influence its 
secondary structure.[18] Upon mutation of the 56VYVY59 region of the C-terminal tail in the 
SARS Corona virus, the secondary structure has changed to a more discrete β-structure.[18]  
 
 
 
Scheme 4.1. (A) SARS CoV-E sequence with TK9 region shown in blue. (B) The three-
dimensional solution structure of SARS CoV-E protein in sodium dodecyl sulfate (SDS) micelle 
(2MM4.pdb). The C-terminal tail, Thr55 – Lys63 adopted alpha helical conformation in micelle, 
makerd by circle, used in this study. (C) The primary amino acid sequence of TK9 or its shorter 
fragments. 
 
To gain further insight, whether the short peptide, TK9 and its variants have a self-
assembling tendency, we carried out detailed biophysical and high resolution analyses of TK9. 
These data demonstrated that TK9 self assembles and forms a β-sheet secondary structure in 
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solution. To support our experimental findings and also to extract out the atomic level 
interactions acting as a driving force for this self-assembly process we performed molecular 
dynamics (MD) simulations. Furthermore, we also studied the ability of TK9 to inhibit the 
aggregation of a 37-residue human islet amyloid polypeptide protein (hIAPP) in order to obtain 
possible structural motifs that may be beneficial for the mitigation of hIAPP aggregation.  
Previous studies have shown that unstructured hIAPP monomers aggregate to form toxic 
intermediates and amyloid fibers that composed of β-sheet peptide structures that are implicated 
in type II diabetes.  Therefore, there is considerable current interest in developing compounds to 
inhibit hIAPP aggregation and islet cell toxicity.  In this context, the amyloid-inhibiting ability of 
TK9 could be useful and aid in the development of potent amyloid inhibitors.    
 
MATERIALS AND METHODS 
Materials and preparation of stock solutions. The parent peptide, TK9 and its shorter 
fragments (Scheme 1) were synthesized on a solid phase peptide synthesizer (Aapptec Endeavor 
90) using Fmoc protected amino acids and Rink Amide MBHA resin (substitution 0.69 mmol/g; 
Novabiochem, San Diego, California) by following a solid phase peptide synthesis protocol 
described elsewhere.[19,20] The C-termini of the peptides are amidated. All the crude peptides 
were further purified by reverse phase HPLC (SHIMADZU, Japan) using a Phenomenix C18 
column (dimension 250 × 10 mm, pore size 100 Å, 5-µm particle size) by linear gradient elution 
technique using Water and Methanol as solvent both containing 0.1% TFA as the ion pairing 
agent. The purity and molecular weight of the eluted peptides were confirmed by MALDI-TOF 
(Bruker, Germany). 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) and deuterium oxide 
(D2O) were purchased from Cambridge Isotope Laboratories, Inc. (Tewksbury, MA). Thioflavin 
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T dye was purchased from Sigma Aldrich (St. Louis, MO). Throughout the experiment HPLC 
grade water was used for sample preparation. hIAPP was purchased from Genscript (Piscataway, 
NJ). hIAPP was prepared by dissolving the peptide in hexafluoroisopropanol (Sigma Aldrich) 
followed by lyophilization. Peptide stock was dissolved in 100 µM HCl (pH 4), sonicated for 1 
min, diluted into the appropriate buffer system and kept on ice until use. 
Circular dichroism. All circular dichroism experiments were performed on Jasco J-815 
spectrometer (Jasco International Co., Ltd. Tokyo, Japan) furnished with a Peltier cell holder and 
temperature controller CDF-426L at 25 ºC. The peptide concentrations were 25 µM for all CD 
measurements. The samples were scanned between 190 to 260 nm wavelength at a scanning 
speed of 100 nm min-1. The data interval was 1 nm and path length 2.0 mm. All data-points are 
the resultant of an average of 4 repetitive scans. All experiments were performed in 10 mM 
phosphate buffer of pH 7.0. Each spectrum was baseline corrected with reference to buffer. The 
data obtained in mill degrees were converted to molar ellipticity (ME) (deg.cm2.dmol-1) and 
plotted against wavelength (nm). 
Fluorescence assays. Tyrosine fluorescence experiments were performed using Hitachi F-7000 
FL spectrometer with a 0.1 cm path length quartz cuvette at 25 ºC. Intrinsic tyrosine fluorescence 
property was used to monitor the self assembly property for tyrosine containing peptides TK9, 
TY5, YR5 using an excitation wavelength of 274 nm and emission in a range of 290-370 
nm.[21] The excitation and emission slit both were 5 nm. The peptide concentrations were 25 
µM throughout the experiment. Thioflavin-T (ThT) experiments were performed on a BioTek 
multiplate reader using an excitation wavelength of 440 nm and emission wavelength of 485 nm. 
Samples were prepared by adding hIAPP (10 µM) to a buffer solution (10 mM phosphate, 150 
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mM NaCl, pH 7.4) containing ThT (20 µM) and varying concentrations of TK9 monomer (0.5 – 
2 equiv). TK9 aggregates for the ThT assay were prepared by incubation at 37 ºC for 7 days. 
Dynamic light scattering. DLS experiments were performed using Malvern Zetasizer Nano S 
(Malvern Instruments, UK) equipped with a 4-mW He-Ne gas laser (beam wavelength = 632.8 
nm) and 173° back scattering measurement facility. All samples were filtered using 0.25-µm 
filter paper (Whatman Inc, NJ) and degassed before use and measured at 298 K using a low 
volume disposable sizing cuvette. The peptide concentration was kept at 10 µM in phosphate 
buffer (pH 7.0) during the duration of the experiment.  
Nuclear magnetic resonance. The synthetic peptide, TK9 and its analogues were dissolved in 
milli-Q water (pH 7.0). All NMR spectra were recorded at 298 K using Bruker Avance III 500 
MHz NMR spectrometer, equipped with a 5 mm SMART probe. Two-dimensional total 
correlation spectroscopy (TOCSY) and rotating frame nuclear Overhauser effect spectroscopy 
(ROESY) spectra of TK9 were acquired in water containing 10% D2O and DSS (2,2-dimethyl-2-
silapentane 5-sulfonate sodium salt) as an internal standard (0.0 ppm for methyl protons). The 
peptide concentration was kept at 1 mM for the sequential assignment and relaxation studies, 
respectively. TOCSY mixing time was set to 80 ms using the MLEV-17 spin-lock sequence to 
ensure coherence transfer via scalar couplings, whereas a 150 ms spin-lock mixing time was 
used for ROESY experiments. The TOCSY and ROESY experiments were performed with 456 
t1 increments and 2048 t2 data points. The residual water signal was suppressed by excitation 
sculpting techniques. The spectral widths were set to 10 ppm in both dimensions with a 
saturation delay of 1.5 sec. Data acquisition and data processing were carried out using 
TopspinTM v3.1 software (Bruker Biospin, Switzerland).  
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The two-dimensional NMR data were assigned and analyzed using SPARKY[22] 
program. The cross peak intensities measured from ROESY spectra were qualitatively classified 
as strong, medium, and weak, which were then converted to upper bound distance limits of 3.0, 
4.0, and 5.5 Å, respectively. The lower bound distance was constrained to 2.0 Å to avoid van der 
Waals repulsion. The backbone dihedral angle (phi, φ) was varied from -30o to -120o to restrict 
the conformational space for all residues. Finally, Cyana 2.1 software was used for structure 
calculation with the help of distance and dihedral angle restraints.[23] Several rounds of 
refinement were performed based on the NOE violations, and the distance constraints were 
accustomed accordingly. A total of 100 structures were calculated, and 20 conformers with the 
lowest energy values were selected to present the NMR ensemble and staring structure for coarse 
grain molecular dynamics simulation. 
A series of one-dimensional proton NMR spectra for TK9 and its analogues were 
recorded at different time intervals to determine their aggregation tendency. The spectra were 
acquired with water suppression with a spectral width of 12 ppm, 128 transients, a relaxation 
delay of 1.5 sec. The spectra were processed and plotted with TopSpin software (Bruker, 
Switzerland) using a line broadening of 1.0 Hz.  
Saturation transfer difference (STD) NMR experiments for a sample containing TK9 (0.5 
mM) and hIAPP monomers (10 µM) were carried at 25 ºC for 12 hours consecutively with an 
interval of 15 min using a Bruker 600 MHz NMR spectrometer equipped with a cryo probe. The 
peptide, hIAPP or its fibril was irradiated at -1 (on-resonance) and at 40 ppm (off-resonance) for 
a duration of 2 s and 128 scans were co-added to get the spectrum. The selective irradiation was 
achieved by a train of Gaussian pulses with 1% truncation for a duration of 49 ms with an 
interval of 1 ms at 50 dB. 
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Relaxation studies. To gain access the atomic level dynamics present one-dimensional spin-spin 
(T1) and spin-lattice (T2) relaxation experiments for TK9 were performed using 500 MHz Bruker 
Avance III NMR spectrometer. T1 experiments were performed using the same protocol that we 
published earlier with different inversion recovery delays starting from 50 ms to 5 s.[24] 
Similarly, T2 measurements were carried out using the CPMG sequence for a set of delays: 2, 6, 
32, 100, 200, 400, 800, 2000, 3000 and 4000 ms.[25]  
Scanning electron microscopy (SEM). The incubated peptide solutions were deposited on a 
glass slide (1 cm2) and dried oven night in air. The slide was then coated with gold for 120 s at 
10 kV voltage and 10 mA current. The samples were viewed on a ZEISS EVO-MA 10 scanning 
electron microscope equipped with a tungsten filament gun operating at 10 kV. 
Transmission electron microscopy (TEM). The 500 µM peptide stock solutions were 
incubated at room temperature for up to 15 days and 10 µL aliquots of the solution were placed 
on 300 mesh Formvar/carbon coated copper TEM grids (Ted Pella, Redding, CA 96049, USA). 
It was allowed to adsorb on TEM grid for about 3-4 minutes and excess volume was removed 
with filter paper. The grid was negatively stained with 5 % (v/v) freshly prepared uranyl acetate 
in water. After 5 minute excess dye was removed and the grids were viewed on a JEOL JEM 
2100 HR TEM microscope operating at 80 kV. A set of TEM samples for TK9 were also viewed 
on a Philips Model CM-100 transmission electron microscope (80 kV, 25,000x magnification) 
Digital images were acquired using Gatan Digital Micrograph 2.3.0 image Capture Software.  
Coarse-Grained Molecular Dynamics Simulations. Coarse-Grained (CG) molecular dynamics 
(MD) simulation of TK9 was performed using Martini model.[26,27] Using this model, TK9 is 
mimicked by 24 beads in a single chain, as shown in Figure S1. Simulation systems were built 
with 20 chains of beaded TK9 placed randomly in a box of size 12 nm. Energy minimization 
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was initially conducted on peptide in a vacuum using the steepest descent method with a 
maximum step size of 0.01 nm and a force tolerance of 10 kJ mol-1 nm-1. Solvation of the system 
was carried out with 59652 CG water molecules (each CG water molecule corresponds to 4 all 
atom water molecules). The solvated system was further minimized using the same parameters as 
that of energy minimization in a vacuum. Then MD simulation was performed using NPT. The 
velocities were assigned according to the Maxwell-Boltzmann distribution at 320 K. 
Temperature was kept at 310 K by the Berendsen method with a time constant of 0.3 ps, and the 
pressure was maintained at 1 bar with a time constant of 3 ps and a compressibility of 3×10-5 bar-
1. The periodic boundary conditions (PBC) were applied. The non-bonded Lennard-Jones (LJ) 
and electrostatic interactions were calculated using a cut off of 1.2 nm. Furthermore, the standard 
shift function in GROMACS was used to reduce undesired noise.[28] Specifically, the LJ 
potential and electrostatic potentials were shifted to zero from 0.9 and 0.0 nm, respectively, to 
the cut off distance (1.2 nm). A time step of 30 fs was used and trajectory was saved every 150 
ps for analysis. The simulation duration was 1 µs. Structural changes in the assembly during the 
simulation run are captured at different time step as shown in (Figure C.2). 
Reverse construction of all atom system. Reconstruction of all atom (AA) system from CG 
was carried out to regain the atomic details. At first, AA particles were placed near to the 
corresponding CG beads and coupled to CG beads by harmonic restraints. This restrained the 
system further and then was processed by simulated annealing (SA); the final relaxed atomic 
model was obtained by the gradual removal of the restraints.[29] 
There construction simulations started from the snapshot at 999 ns time step of the CG 
simulations as illustrated in Figure C.3.The atomistic simulations were carried out with a 2-fs 
integration time step, and the temperature was controlled by coupling to a Nosé–Hoover 
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thermostat with a time constant of 0.1 ps.[30] Because of the random initial placement of the 
atomistic particles, no constraints were applied in the reconstruction simulations, except for SPC 
water. 
For the simulations of the TK9, the 53 a6 parameter set of the GROMOS united atom 
force field was used.[31] The system was simulated within periodic boundary conditions. Non-
bonded interactions were calculated using a triple-range cut off scheme: interactions within 0.9 
nm were calculated at every time step from a pair list, which was updated every 20 fs. At this 
time steps, interactions between 0.9 and 1.5 nm were also calculated and kept constant between 
updates. A reaction-field contribution was added to the electrostatic interactions beyond this 
long-range cut off, with Єr=62. In the simulations of bulk SPC water, at win range cut off 
scheme was used, with a single cut off at 0.9 nm and a pair list up dated every 20 fs. Here, along-
range dispersion correction was applied in addition to the reaction field. Other simulation 
parameters are as given in Table C.1. 
RESULTS 
Design considerations for TK9 and its variants. The SARS-CoV Envelope region (Cov E) 
(Scheme 4.1A) contains a relatively hydrophobic C-terminal region (Scheme 4.1B), composed of 
an alpha helix (α-helix) at the trans-membrane followed by a β-structured region, 
55TVYVYSRVK63, or TK9, which has been considered an essential sequence content for its 
function. This region has been predicted to be responsible for directing the protein to the Golgi 
region.[18,32,33] It should be mentioned that this type of motif remains conserved in other 
corona viruses and is abundantly expressed in infected cells and may also be critically involved 
in viral protein assembly.[34,35] Fourier transform infrared (FT-IR) spectroscopy investigations 
have also shown that this portion of the protein can intrinsically adopt both a random coil and β-
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sheet conformation in the absence of a membrane environment.[32] The folding domain (β-
structured region), which contains the sequence of TVYVYSRVK and its fragments (Scheme 
4.1B) contain residues and sequences similar to those of amyloid proteins. This has led to the 
hypothesis that TK9 may have similar properties to the folding domains of amyloid proteins 
(e.g., amyloid-β), where certain residue regions have limited water solubility and adopt a β-sheet 
structure and may aggregate to form amyloid-like fibrillar species. This observation has made 
TK9 and its derivatives insightful nanostructure systems to study protein assembly and 
mechanism of folding.[36] Specifically, residues I46 – V62 contain branched and bulky side 
chains which may favor the formation of β-sheet structures.[37] The first five residues of TK9, 
TY5 (TVYVY) (Scheme 4.1C) also contain a peptide motif demonstrated to form amyloid-like 
fibrils; therefore, this short peptide fragment and its derivatives namely, TY5, YR5 and SK4 
(Scheme 4.1C) were chosen as model systems to give possible insights into amyloid folding 
events. These sequence motifs containing branched, hydrophobic residues as well as residues, 
which can form H-bonds, has been shown to have a higher aggregation propensity as seen with a 
Leu-Enkephalin mutant and VEALYL.[38-41] 
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Figure 4.1. (A) Dynamic light scattering (DLS) plot for TK9 (red), TY5 (blue), YR5 (green) 
and SK4 (pink);the intensity vs. size distribution bar diagram are plotted at different time 
intervals. (B – E) Circular Dichroism (CD) plots of secondary structure of TK9 and its fragments 
measured after freshly preparation and incubation with 15 days.  
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TK9 and TY5 are more prone to aggregation with increased incubation time. Dynamic light 
scattering (DLS) is an analytical method used to establish the size distribution of an ensemble of 
particles from Brownian motion property in solution.[42] Here, we employed DLS to access the 
size distribution of the supramolecular structures formed during different incubation periods. It is 
seen that freshly prepared TK9 or its analogues, TY5, YR5 and SK4 (Scheme 4.1C) show a 
narrow size distribution pattern with a hydrodynamic diameter of ~ 27 nm (Figure 4.1A and 
Figure C.4). The narrow distribution confirms that the peptides are monomer in freshly dissolved 
solution at early time points. However, with increasing the incubation time period for TK9, TY5 
and YR5, the size distribution profile became wider, which accounts for the presence of 
polymeric subunits in solution (Figure C.4). After 15-days of incubation, clear distinctions in the 
hydrodynamic diameters were observed for the peptides. TK9 and TY5 showed the highest 
change in hydrodynamic diameter, whereas YR5 showed a moderate change in size distribution 
only after 25 days of incubation (Figure C.4). On the other hand, SK4 showed a negligible 
amount of change in hydrodynamic diameter within a period of 25 days of incubation, which 
suggests its lower aggregating propensity. This trend pointed out that aromatic amino acids (Tyr) 
of these peptides may contribute significantly to the shape and size of their nanostructure 
assemblies and that polar amino acids may not directly influence their size. Overall, our DLS 
results proved a similar aggregation behavior of the parent peptide TK9 and its N-terminal 
fragments TY5 and YR5 can be seen after 25 days of incubation. 
Furthermore, circular dichroism (CD) spectroscopy was used to monitor the secondary 
structure of the peptide fragments at different incubation time (Figure 4.1B-E). Freshly prepared 
TK9 and its truncated shorter fragments showed a strong negative maximum at ~195 nm, 
characteristic of random coil conformation of the peptides or proteins (Figure 4.1B-E). 
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Interestingly, after 15 days of incubation, samples containing TK9 and TY5 showed distinct β-
sheet type CD spectral signature consisting of positive maximum at 200 nm and a negative 
maximum at 215 nm due to n - π* and π - π* transition (Figure 4.1B and 4.1C). In contrary, the 
CD spectrum of YR5 showed two peaks, one at ~ 198 nm and another broad peak at ~ 215 nm 
(Figure 4.1D). Similarly, SK4 showed a large broadening of peaks (Figure 4.1E). This result 
clearly signifies that both YR5 and SK4 are highly dynamic in nature and there may be 
conformational exchange between random coils to β-sheet in a dynamic state (Figure 4.1D-E). 
Overall the CD data identified that TK9 and TY5 undergo structural reorganization from random 
coil to β-sheet over time while the other fragments are not prone to this similar conformational 
change. 
Morphology of TK9 and its variants. To understand further about the morphological change of 
the nanostructures of the peptide self-assembly, various electron microscopic techniques such as 
transmission electron microscopy (TEM) and scanning electron microscopy (SEM) were 
employed. TEM data revealed that freshly prepared TK9 did not show any measureable structure 
(data not shown), which is in very good agreement with the CD data (Figure 4.1B). However, 
TEM analysis of the sample containing TK9 alone with 10 days of incubation displayed a dense 
fibrillar network which has slight amorphousity and unbranched characteristics (Figure 4.2A and 
inset, respectively), suggesting that the peptide region are able to form β-sheet morphology, 
which could be in good agreement with the TEM images of β-sheet forming amyloid fibrils 
originated from either Aβ or hIAPP.[43] The effect of fibrillation was pronounced for both TK9 
and TY5 which sequence consisting beta branched amino acids such as Thr1-Val2-Tyr3-Val4-
Tyr5 residues. In addition, these residues are prone to form a plane of β-sheet structures (Figure 
4.2B). The structure of TK9 emphasized that the rate of nucleation for the β-sheet formation 
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could be slower due to presence of two positive charge residues, Arg7 and Lys9 at the C-
terminal of the peptide sequence, but our DLS data suggests that they fibrilize with similar 
kinetics. In contrast, YR5 and SK4 did not show any defined nanostructure by TEM (data not 
shown), which could be attributed to the sole presence of charged residues at the C-terminal of 
TK9 sequence which did not allows the peptides to self assemble. 
 
 
 
Figure 4.2. Transmission and scanning electron micrographs showing fibrillar nanostructure 
morphology for TK9 (A and C) and TY5 (B and D), respectively. 
 
Subsequently, SEM experiments were performed to understand the self-assembly 
propensity of TK9 and its analogues after incubation at 37 °C for several days (Figure 4.2C-D). 
TK9 exhibited well-defined, branched, long rod-like fibers (Figure 4.2C) after 25 days. The 
truncated analogue, TY5 showed a dense nano-tubular architecture (Figure 4.2D). These results 
indicate that both TK9 and TY5 form fibrils in solution. In contrary, the central region of the 
peptide sequence, YR5 showed an amorphous like architecture rather than uniformly well-
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defined fibers and tubes (Figure C.5). The C-terminal truncated peptide, SK4 consists of the 
charged residues (Ser6, Arg7 and Lys9) did not allow the peptide to adopt any particular 
structure (Figure C.5). Taken together, TK9 and TY5 self assembled to adopt a well-defined 
nanostructure confirmed by both TEM and SEM. 
 
 
 
Figure 4.3. (A) Tyrosine fluorescence of TK9 (red), TY5 (black) and YR5 (blue) monitoring 
increase in Tyr fluorescence signal as peptide aggregates. (B) Thioflavin T (ThT) fluorescence 
assay measuring β-sheet rich fibril formation of freshly dissolved TK9 (black) and after 16 days 
of TK9 incubation (red). 
 
Fluorescence measurements to monitor peptide aggregation. The intrinsic fluorescence 
property of tyrosine (Tyr) for TK9, TY5 and YR5 was used as a probe to determine structural 
perturbation of the peptides upon incubation and the putative role of the interactions involved. It 
is noteworthy to mention that there are two Tyr residues in each of the peptide. The intensity for 
emission maxima of Tyr was increased gradually with increasing the incubation time period for 
TK9 as well as TY5 and YR5 (Figure 4.3A). This enhancement was attributed to the change in 
the local environment of the fluorophore from a hydrophilic to a more hydrophobic environment. 
Initially, the Tyr residues were randomly oriented in solution where solvent molecule could 
easily quench their fluorescence intensity. However, the fluorescence emission maxima 
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increased almost 4 times for TK9 and TY5 from 5 days of incubation time to 25 days of 
incubation time (Figure 4.3A). In contrast, the emission maxima of YR5 increased much less 
compared to that of TK9 (Figure 4.3A). Conversely, the incremental increase in fluorescence 
intensity of emission maxima for YR5 was negligible and reached a plateau after 25 days of 
incubation (Figure 4.3A), suggesting YR5 may not form an ordered aggregate in solution. 
 
 
 
 
Figure 4.4. (A) Amide proton chemical shift regions of 1HNMR spectra of TK9 (A), TY5 (B), 
YR5 (C) and SK4 (D); (E) average decrease in peak intensity for each peptide. Spectra obtained 
after 0, 15 and 25 days incubation period are overlaid.  
 
Furthermore, thioflavin T (ThT) assays was performed to measure the higher order 
aggregation of TK9 over time. It is noteworthy to mention that, ThT is small molecule and 
specifically bind to the β-sheet rich amyloid fibrils.[44] Figure 4.3B shows the fluorescence 
intensity of ThT, binding to peptide, TK9. The freshly dissolved TK9, incubated with ThT 
demonstrated very low fluorescence intensity. However as TK9 allowed to self assemble for 16-
days, a greater extent of fluorescence intensity of ThT at approx. 490 nm was displayed, 
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indicative of the presence of a β-sheet rich species. This result further confirms that the 
aggregation propensity of TK9 in solution increases over time. Collectively, these results suggest 
that the non-covalent π-π stacking interaction between the Tyr residues in the supramolecular 
structures of the aggregated states create a hydrophobic environment (β-sheet structure) where 
the entrance of water molecule is restricted and hence enhances the fluorescence emission 
maxima and interacts with the ThT dye.  
 
 
 
Figure 4.5. The residue-wise relaxation profile for freshly prepared TK9 (blue) and 25 days 
incubated TK9 (red). (A) Longitudinal relaxation rate (R1) and (B) transverse relaxation rate (R2) 
are plotted for each residue of TK9. 
 
1H NMR confirms the aggregation propensity of TK9. NMR spectrum of TK9, or its 
analogs, exhibited well-resolved narrow amide proton peaks indicating that the peptides are 
highly dynamic in aqueous solution (Figure 4.4). A 2D TOCSY, in conjunction with ROESY, 
spectrum was used to assign the peaks (Figure C.6). The ROESY spectrum of TK9 contained 
intra-residue αN (i, i) as well as sequential, αN (i, i+1) ROEs between backbone and side chain 
resonances (Figure C.6A), and no medium range αN (i to i+2/i+3/i+4) or long-range αN (i to 
>i+5) cross peaks were observed, indicating that the peptide does not adopt any folded 
conformation (Figure C.6 and C.7). In addition, ΔHα values of the residues did not show any 
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pattern of secondary structure (data not shown). A total of 47 ROEs (Table C.2) were used to 
calculate the random coil structure of TK9 (Figure C.7), which is also confirmed by the CD data 
(Figure 4.1).  
 
 
Figure 4.6. (A) Pairwise hydrogen bond analysis between any two monomers. Cumulative % H 
bond occupancy is calculated for respective residue pair in each peptide. (B) Percentage of H-
bond occupancy of respective residue in each monomer was calculated to understand the amino 
acid-solvent interactions. Red bar represents the assembled and blue bar represents unassembled 
aggregation of each monomer of TK9. (C) Total number of hydrophobic interactions for 
respective residue pair is calculated for all the peptides forming cluster. (D) Oligomeric structure 
of TK9 is stabilized by hydrophobic hub consisting Tyr, Val, Ser and Thr residues. Positively 
charged residues are exposed to water. 
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To determine the extent of aggregation as a function of time, we collected a series of 1D 
1H NMR spectra of all the peptides in different time intervals of incubation. Figure 4.4 shows the 
amide proton chemical shift regions for TK9 and its analogues at the same time intervals. While 
freshly prepared peptides exhibited well-dispersed narrow peaks from amide protons, line 
broadening was observed with time of incubation (Figure 4.4A-4D). TK9 and TY5 showed the 
highest amount of line broadening with respect to time, whereas SK4 showed the least line 
broadening (Figure 4.4E). The observed line broadening in NMR spectra could be due to the 
formation of high molecular weight peptide aggregation. This effect was further confirmed by 
proton relaxation studies. 
1H NMR relaxation studies are used extensively as a sensitive probe to investigate the 
weak interactions (dissociation constant, Kd ~ µM to mM range) in peptide oligomerization.[45] 
The formation of high molecular weight oligomers, associated with an increase in correlation 
times, (τc) is revealed by a decrease in longitudinal relaxation rates (R1) as reported in Figure 
4.5A for the N-terminal residues of TK9, Val2-Arg7 (Figure 4.5A). On the other hand, the 
increase in the aggregation size of the species resulted an increase in the transverse relaxation 
rates (R2) for all the residues of TK9 in the aged sample as compared to that in the freshly 
prepared sample as shown in Figure 4.5B. However, the charged C-terminal residues, Arg7-
Val8-Lys9, that are more mobile showed less increment of R2 values for the aged sample of 
TK9. Overall, the observed relaxation data suggest the formation of high molecular weight 
oligomers in aged samples of TK9. 
Simulations suggest that both local and global orientation of TK9 may influence 
aggregation. The above experimental result motivated us to determine the mechanism of 
aggregation of a small peptide, TK9. Interestingly, among the nine amino acid residues, there are 
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two aromatic amino acid residues, Tyr, three hydrophobic Val residues, two positive charge Lys 
and Arg and two β-branched amino acid residues, Thr and Ser. The NMR derived extended 
conformation of TK9 (Figure C.6C) was used as an initial structure for the coarse grained (CG) 
molecular dynamics (MD) simulation. It is noteworthy to mention that the self-assembly of a 
short peptide occurs at a µs time scale, and hence it is a time consuming process to carry out all 
atom MD simulation.[46] To overcome this problem, coarse-grained MD simulation was 
adopted to study the aggregation of TK9 with twenty TK9 peptide chains. 
Figure C.2 summarizes the stages of aggregation of TK9. Interestingly, the scattered 
monomers started self-assembling after 27 ns of simulation and the cluster size was increasing as 
the time progressed. Finally, after 999 ns of simulation, fifteen out of twenty TK9 peptide chains 
were self-assembled to form the TK9 aggregate (Figure C.2). The remaining five TK9 
monomers were still scattered after 1 µs of simulation. Next, we wanted to understand the 
driving force of the aggregation for TK9. The secondary structure analysis of the assembled as 
well as the scattered molecules were performed using the Stride web interface.[47] Interestingly, 
we found that the 60% of conformation of assembled peptide possess a beta turn and more than 
35% of conformation exists as random coil (Table C.3).  
Closer inspection indicated that the self-assembly of TK9 (Figure 4.6) was stabilized by a 
variety of interactions, such as H-bonding, electrostatic, π-cation and van der Waals. The C-
terminal positively charged Lys9 residue of TK9 contributed for a H-bonding interaction with 
Thr1 and with Ser6. In addition, H-bonding contributions were also observed between Thr1-
Ser6, Tyr3-Tyr5, Val4-Tyr5, Val2-Val4 and Thr1-Thr1 of TK9 in an assembled state. Apart 
from the H-bonding interactions between two self-assembled monomers, polar residues such as 
Arg7 and Lys9 formed numerous intermolecular salt bridge interactions (Table C.4). 
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Hydrophobic contacts were also observed between Val2-Tyr3, Val4-Tyr3, TYR5-Val4, Val2-
Val4, Val2-Tyr5 and Tyr3-Val8, which may also play an important role in the aggregated form 
of TK9 (Figure 4.6). Interestingly, Tyr3-Tyr3, Tyr5-Tyr5 and Tyr3-Tyr5 aromatic interactions 
between two monomers of TK9 aggregates were crucial for stabilization. This result was in very 
good agreement with the Tyr fluorescence intensity enhancement in the aggregated state (Figure 
4.6). A few cation-π interactions between Tyr3-Arg7, Tyr5-Arg7 and Tyr5-Arg9 were also 
observed in the fibrillar TK9 (Table C.5). 
 
 
 
Figure 4.7. (A) Comparative analysis of the average SASA for each residue in assembled and 
unassembled state. Black represents the assembled state while red represents the unassembled 
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state. (B) ΔSASA (ΔSASA=SASAunassembled -  SASAassembled) values for each residue. (C) Surface 
view of cluster illustrating polarities of residues with color discrimination.  
 
Solvent accessible surface area (SASA) data was evaluated to suggest the conformation 
of the biomolecule. The SASA values of each residue of TK9 aggregate as well as in the 
scattered monomers after 1 µs of simulation were calculated (Figure 4.7) and it was clear that the 
overall SASA values for all the residues in the cluster or aggregated form was lower, whereas, 
the same amino acid residues in the scattered peptides (monomer) were much higher. The 
standard deviation of SASA values of each residue of scattered peptides was less compared to 
that of aggregated peptides. This behavior could be due to folded conformation in the aggregated 
form and hence they were less accessible to the solvent. On the other hand, the short peptide 
TK9 is highly dynamic in nature and therefore, the peptide is more solvent exposed in the 
unfolded form. Interestingly, the C-terminal residues, Arg7, Val8 and Lys9 showed comparably 
higher SASA values both in the scattered as well as in the aggregated form (Figure 4.7). Taken 
together, the central stabilization of the assembly of TK9 was due to the strong van der Waals 
interactions between hydrophobic Val residues as well as between aromatic Tyr residues. In 
comparison, the Arg7 and Lys9 residues of TK9 aggregates were pointing towards the solvent to 
form H-bond with the solvent water molecules.  
TK9 inhibits hIAPP aggregation. In order to uncover the potential role of the self-assembling 
TK9 peptide on amyloid aggregation, it was co-incubated with freshly dissolved hIAPP and 
assayed using ThT to monitor β-sheet rich fibril formation. At a stoichiometric concentration of 
TK9 monomer, hIAPP still adopted a normal course of aggregation; however, the lag phase was 
increased and the total fibrillar hIAPP fluorescence intensity was decreased (Figure 4.8A). With 
the increased concentration of TK9, hIAPP aggregation was completely diminished. Similarly, 
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incubation of freshly dissolved hIAPP with excess TK9 over 8 hr displayed mainly a random 
coil peptide in solution as shown by CD experiments (Figure 4.8B). When TK9 fibril was added 
to hIAPP solution, aggregation of hIAPP was slightly modified, suggesting possible interactions 
between TK9 and hIAPP.  
 
 
 
Figure 4.8. (A) ThT fluorescence assay of hIAPP (black) solution incubated with 1 (red) and 2 
(blue) equivalents of TK9;  ThT aggregation of TK9 peptide in solution is shown in the green 
trace. (B) CD spectra of freshly dissolved hIAPP (black) and hIAPP incubated over 6 hours with 
2 equivalents of TK9 at the indicated time intervals of aggregation. (C) One dimensional 1H 
NMR spectrum of freshly dissolved TK9 in hIAPP (monomer) (top, control); STD spectrum in 
the presence of hIAPP monomer at t = 12 h. (middle) and in the presence of hIAPP fibril 
(bottom).  
 
The inhibition of hIAPP aggregation by TK9 was further confirmed by 1H STD NMR 
experiments. STD has become a valuable technique to map the interaction of ligands with 
biomolecules.[48-50] Freshly prepared hIAPP monomers were added to a solution of TK9 
monomers and monitored by NMR for more than 12 hr. Receptor, hIAPP, as well as the ligand, 
TK9, are low-molecular weight molecules; therefore, no STD signals from TK9 in the presence 
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of hIAPP monomers were observed due to the fast tumbling of TK9. However, if hIAPP 
fibrillizes, it should be possible to transfer the magnetization from the large-size hIAPP fibrils to 
TK9 peptide in STD experiments. But, the fact that we did not observe STD signal within a 
period of 12 hours indicates that hIAPP did not exist in fibrillar form (Figure 4.8C), as hIAPP (in 
the absence of TK9) completely fibrilizes within 3 hours at the same condition as seen by the 
ThT assay (Figure 4.8C). In addition, when TK9 monomers were incubated with hIAPP fibrils, a 
pronounced STD signal was observed from aromatic as well as aliphatic amino acid residues, 
indicating that the aromatic and methyl protons are responsible for interacting with fibrillar 
hIAPP. These observations confirm the ability of TK9 to inhibit hIAPP aggregation to form an 
ordered secondary structure.  
DISCUSSION 
According to the current trend in nanoscience, synthetic amphiphilic small peptides 
emerge as versatile building block for the fabrication of supramolecular architecture.[51] The 
ability of these peptides to assemble into ordered nanostructures may help to better understand 
the natural misfolding pathway of systems such as amyloid proteins.[52] In these systems, short 
peptide fragments in the wild-type sequence (KLVFF for amyloid-β and NFGAIL for hIAPP) 
have been identified to be responsible for β-sheet formation thus more clearly investigating the 
properties and features of small peptide assemblies can help in better understanding larger 
protein systems.[53-55] The self-assembly regions have also served as a template to rationally 
design amyloid inhibitors by blocking β-sheet formation, therefore; short peptide fragments of 
amyloid proteins can also help elucidate possible sequence motifs for therapeutic design and 
development.[56-58] 
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The aim of this study has been to reveal self-assembly activity of the ultra small peptide, 
TK9 and its variants through biophysical, NMR and computational methods. TK9 and TY5 both 
contain branched, bulky amino acids and a specific sequence (VxVx, Scheme 4.1) that has been 
shown to be prone to amyloid-like aggregation.[59] Over time, TK9 spontaneously aggregated in 
aqueous solution as seen by DLS (Figure 4.1) to adopt rod-like fibrillar morphology, confirmed 
by microscopic studies (Figure 4.2). Interestingly, the aggregation was β-sheet rich, examined by 
the increase in ThT fluorescence (Figure 4.3). All four peptides adopt a random coil monomeric 
conformation at early time points; however, CD experiments confirmed that TK9 and TY5 form 
into a β-sheet containing fibrillar species after incubation over days (Figure 4.1B and 4.1C). In 
addition, because of the presence of the “amyloid aggregation-prone” sequence motif, a further 
explanation for the aggregation propensity of TK9 and TY5 may be the increase in hydrophobic 
and aromatic residues, which may favor hydrophobic contacts and π-π interactions as well as 
undergo a transition to β-sheet during self-assembly more readily than peptides with aliphatic 
residues.[59] 
Structurally different, YR5 and SK4, which do not contain the aggregation-prone 
sequence, did not show this transition to β-sheet nor did they show an enhanced ThT 
fluorescence, suggesting an ill-defined secondary structure. The distribution profile of the 
peptides is also varied upon aggregation as suggested by the DLS studies (Figure 4.1A). As the 
peptides were incubated, the size of the species increased, which may be attributed to the fibril-
like aggregates formed in the case of TK9 and TY5. The π-π interactions could be the governing 
factor for the folding of the peptide into supramolecular assemblies as seen by Tyr fluorescence 
experiments (Figure 4.3). As TK9 is allowed to self-assemble, it forms a hydrophobic core, 
which does not allow for interactions with water, and thus an enhancement in the Tyr 
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fluorescence signal by neighboring Tyr residues. Coarse grain MD simulation confirms that the 
self-assembled oligomer of TK9 is stabilized by hydrophobic amino acid residues such as Tyr 
and Val from individual monomers to form a hydrophobic hub and all the charge residues such 
as Arg7 and Lys9 are exposed to water (Figure 4.6). In contrary, the solvent quenches the 
fluorescence intensity of TK9 or TY5 monomer (Figure 4.3). However, a well-defined 
secondary structure of YR5, the central region of TK9, was not observed. In order to probe the 
mechanistic insights of self-assembly of a short peptide at an atomic resolution, NMR 
spectroscopy was carried out. 
Proton NMR and relaxation studies further confirm the presence of high molecular 
weight oligomers in aged samples. In 1H NMR spectra, amide resonances are observed for all of 
the peptides at initial time points. As the peptides are allowed to self-assemble, significant line 
broadening is visible for TK9 and TY5, whereas a lesser broadening is seen for YR5 and SK4 
over the time course (Figure 4.4). The line broadening observed for TK9 or TY5 peptides 
confirms the low correlation times with millisecond to microsecond time scale of motion 
between several states of micelle-like aggregation. This dynamic behavior may further confirm 
an aggregation process occurring in solution, specifically the formation of high molecular weight 
assemblies that tumble slowly in NMR time scale, which gave rise to an increased rotational 
correlation time (Figure 4.5). The TOCSY and ROSEY data, taken of freshly prepared 
monomers, show no medium or long range cross peaks (or ROEs), confirming the absence of a 
well-defined secondary structure (possibly random coil) prior to incubation (Figure C.6). 
Furthermore, the applications of these self-assembled peptides are of great value since 
they do have interesting intrinsic properties; however, their role in understanding protein-protein 
interactions may also be useful. Investigations of the interaction between amyloid proteins and 
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other biologically relevant proteins have been of great interest. Specifically, reports regarding the 
interaction of co-secreted proteins, hIAPP and insulin, has shed light into the involvement of a 
protein on amyloid formation.[60,61] Aforementioned, small peptide sequence from the native 
protein have been utilized in the design of amyloid inhibitors due to their ability to contain self-
recognition motifs which can interact with the target protein through hydrophobic and 
electrostatic interactions and prevent polymerization to fibrils.[56,62,63] In order to study this, 
we tested the inhibitory activity of TK9 against hIAPP, an amyloid protein suggested to be a 
pathological feature of type-2 diabetes. Our experimental results indicate that the amyloid-
inhibition properties of TK9 monomers are concentration dependent as shown in Figure 4.8. 
This observation is similar to that shown for amyloid-inhibiting properties of a 9-residue peptide, 
NK9 (or 45NIVNVSLVK53) adopted from SARS CoV E-protein, against the fibrillation of 
insulin.[64] Interestingly, TK9 monomers are able to modify the aggregation kinetics of hIAPP 
and completely inhibit the fibril formation upon incubation with excess amount of a TK9. This 
result was further verified by STD NMR experiments, which showed that upon incubation of 
hIAPP monomers with excess TK9 monomers, no pronounced STD effect was observed 
indicating the presence of a small, insufficient amount of hIAPP fibers. On the other hand, when 
TK9 monomers are present in a solution along with hIAPP fibrils, a strong STD signal was 
observed, confirming an interaction between the two peptides.  
Overall, the study of self-assembled peptides nanostructures can serve, as useful systems 
for understanding more global systems, like amyloid proteins kinetics and aggregation at the 
atomic level. Herein, the aggregation properties of TK9 and its variants were characterized 
through biophysical, spectroscopic and simulated studies, and it was confirmed that the structure 
of these peptides influence their aggregation propensity and fibrillar morphology. TK9 
 94 
underwent a transition to a more β-sheet rich structure, which adopted a fibril-like shape. These 
aggregates were further investigated through simulations to understand more clearly the possible 
intra- and inter peptide interactions at the molecular level. As described here, self-assembly 
peptides may also be useful templates for designing amyloid inhibitor. These self-assembly 
systems may also be used in understanding the molecular and structural biology which will 
inspire the design and synthesis of increasingly complex self assembled biomaterials for 
biomedicine. Furthermore, investigations to probe the structural characteristics of these peptides 
in the presence of membrane can also be of great value since the amyloid beta or hIAPP protein 
interacts with membrane before going to fibrillation.[65-67] Therefore, instead of using the 
entire protein of amyloid-β or hIAPP in membrane, this peptide can be a nanoindicator to 
understand the structural insight at the membrane surface for the mechanism of fibrillation 
process.  
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